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A B S T R A C T
Background
The uptake of clinical practice guidelines (CPGs) is inconsistent, despite their potential to improve the quality of health care and patient
outcomes. Some guideline producers have addressed this problem by developing tools to encourage faster adoption of new guidelines.
This review focuses on the effectiveness of tools developed and disseminated by guideline producers to improve the uptake of their
CPGs.
Objectives
To evaluate the effectiveness of implementation tools developed and disseminated by guideline producers, which accompany or follow
the publication of a CPG, to promote uptake. A secondary objective is to determine which approaches to guideline implementation
are most effective.
Search methods
We searched the Cochrane Effective Practice and Organisation of Care (EPOC) Group Specialised Register, Cochrane Central Register
of Controlled Trials (CENTRAL); NHS Economic Evaluation Database, HTA Database; MEDLINE and MEDLINE In-Process and
other non-indexed citations; Embase; PsycINFO; CINAHL; Dissertations and Theses, ProQuest; Index to Theses; Science Citation
Index Expanded, ISIWeb of Knowledge; Conference ProceedingsCitation Index - Science, ISIWeb of Knowledge;HealthManagement
Information Consortium (HMIC), and NHS Evidence up to February 2016. We also searched trials registers, reference lists of included
studies and relevant websites.
Selection criteria
We included randomised controlled trials (RCTs) and cluster-RCTs, controlled before-and-after studies (CBAs) and interrupted time
series (ITS) studies evaluating the effects of guideline implementation tools developed by recognised guideline producers to improve
the uptake of their own guidelines. The guideline could target any clinical area.
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Data collection and analysis
Two review authors independently extracted data and assessed the risk of bias of each included study using the Cochrane ’Risk of bias’
criteria. We graded our confidence in the evidence using the approach recommended by the GRADE working group. The clinical
conditions targeted and the implementation tools used were too heterogenous to combine data for meta-analysis. We report the median
absolute risk difference (ARD) and interquartile range (IQR) for the main outcome of adherence to guidelines.
Main results
We included four cluster-RCTs that were conducted in the Netherlands, France, the USA and Canada. These studies evaluated the
effects of tools developed by national guideline producers to implement their CPGs. The implementation tools evaluated targeted
healthcare professionals; none targeted healthcare organisations or patients.
One study used two short educational workshops tailored to barriers. In three studies the intervention consisted of the provision of
paper-based educational materials, order forms or reminders, or both. The clinical condition, type of healthcare professional, and
behaviour targeted by the CPG varied across studies.
Two of the four included studies reported data on healthcare professionals’ adherence to guidelines. A guideline tool developed by the
producers of a guideline probably leads to increased adherence to the guidelines; median ARD (IQR) was 0.135 (0.115 and 0.159
for the two studies respectively) at an average four-week follow-up (moderate certainty evidence), which indicates a median 13.5%
greater adherence to guidelines in the intervention group. Providing healthcare professionals with a tool to improve implementation of
a guideline may lead to little or no difference in costs to the health service.
Authors’ conclusions
Implementation tools developed by recognised guideline producers probably lead to improved healthcare professionals’ adherence to
guidelines in the management of non-specific low back pain and ordering thyroid-function tests. There are limited data on the relative
costs of implementing these interventions.There are no studies evaluating the effectiveness of interventions targeting the organisation
of care (e.g. benchmarking tools, costing templates, etc.), or for mass media interventions. We could not draw any conclusions about
our second objective, the comparative effectiveness of implementation tools, due to the small number of studies, the heterogeneity
between interventions, and the clinical conditions that were targeted.
P L A I N L A N G U A G E S U M M A R Y
Effectiveness of tools developed and disseminated by guideline producers to improve uptake of their guidelines
Background
Clinical practice guidelines (CPGs) are evidence-based recommendations for healthcare professionals about the care of patients with
specific conditions. The uptake of CPGs by healthcare professionals is inconsistent, despite their potential to improve the quality of
health care and patient outcomes. Some guideline producers have addressed this problem by developing tools to encourage the adoption
of new guidelines.This review focuses on the effectiveness of tools developed and distributed by recognised guideline producers to
improve the uptake of their CPGs.
Characteristics of included studies
Researchers from Cochrane searched the literature up to February 2016 and identified four randomised studies evaluating the effects
of tools developed by recognised guideline producers to implement their guidelines. These were developed by guideline producers in
France, the Netherlands and in the USA and Canada. In all four studies the interventions targeted the healthcare professional. None of
the tools specifically targeted the organisation of care or the patient. The clinical conditions, and the healthcare professionals’ behaviour
targeted by the CPG, varied across studies, as did the tools used to improve guideline implementation.
Key results
Two of the four included studies reported on how well healthcare professionals stick to guideline recommendations when providing
care to their patients, depending on whether they received a CPG with a tool aimed at improving the use of the CPG, or if they received
the CPG only. The results of this review show that healthcare professionals who received a guideline tool together with the CPG on
the management of non-specific low back pain or ordering thyroid-function tests probably stick more closely to the recommendations,
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compared with those who received the CPG only. A guideline tool aimed at improving the use of a guideline, may lead to little or no
difference in cost to the health service.
Certainty of the included evidence
The included evidence was from randomised controlled trials, which is considered the highest level of evidence. However, due to high
risk of bias in the included studies our confidence in the effect on observing guideline recommendations was moderate. Our confidence
in the evidence for cost effectiveness was low, since only a single study provided evidence for this comparison.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Clinical practice guideline (CPG) + implementation tool compared with CPG only for adherence to guidelines
Patient or population: Healthcare professionals (physiotherapists, hospital physicians) providing care for people with
dif f erent clinical condit ions (pat ients with non specif ic low back pain, pat ients with symptoms indicat ing a need for a thyroid
funct ion test)
Setting: Private physiotherapy clinics in the Netherlands, general hospitals in France
Intervention: CPG + guideline implementat ion tool (e.g. training workshops, paper-based materials and order forms,
reminders, web-based tools)
Comparison: CPG only













vided to healthcare pro-
fessionals as an aid
to improve the use
of a CPG probably
lead to improved adher-
ence with the CPG, as
compared to guidelines
only. Median ARD: 0.
135 (0.115 to 0.15.9) at
mean 4 weeks follow-
up
68 physio- therapy





2 of the 4 included stud-
ies reported a proxy
measure for adherence
to guidelines, and re-
sults f rom these stud-
ies could therefore not
be included in the ARD
calculat ion
Costs Guideline tools aimed
at improving the use of
guidelines may lead to
lit t le or no dif ference in
healthcare costs





1 trial reported no dif -
ference in mean direct
annual cost* per pa-
t ient between interven-
t ion and control groups.
1 French paper belong-
ing to 1 of the in-
cluded trials (6 hospi-
tals) and report ing on
costs awaits transla-
t ion
* Direct costs included costs of the disseminat ion of the guideline and healthcare resource use by the pat ient
GRADE Working Group grades of evidence
High certainty: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and
may change the est imate.
Low certainty: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is
likely to change the est imate.
Very low certainty: We are very uncertain about the est imate
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1We downgraded the certainty of the evidence one step due to high risk of bias.
2We downgraded the certainty of the evidence two steps due to imprecision.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
B A C K G R O U N D
The uptake of clinical practice guidelines (CPGs) is inconsistent,
despite their potential to improve the quality of health care and
patient outcomes (Grol 2003; Schuster 1998; Seddon 2001). A va-
riety of tools to improve the uptake of CPGs have been developed,
but not always by the guideline producers themselves. This review
focuses on the effectiveness of tools developed and distributed by
guideline producers to improve the uptake of their CPGs. These
tools are either embedded within a guideline, for example tailoring
a guideline recommendation for a particular user group, or they
accompany the CPG, for example interactive learning modules
developed to support the use of a CPG.
Description of the condition
CPGs have the potential to improve healthcare delivery and out-
comes, but the adoption of guidelines by healthcare professionals
and health system managers is inconsistent, and gaps remain be-
tween recommended care and clinical practice. Previous system-
atic reviews have identified a range of interventions to support the
implementation of guidelines (Grimshaw 2004). However, most
of these have been developed independently of the producers of
guidelines. In response to this some guideline producers have de-
veloped tools to improve the uptake of their CPGs. Some of these
interventions focus on improving the skills needed to apply ev-
idence to practice and others aim to integrate the content of a
CPG into a local healthcare system. The value of these tools has
been questioned by theUKNational Institute forHealth and Care
Excellence (NICE), (New Reference, Leng 2013 [pers comm]) as
they are an additional investment for the guideline producer, and
the evidence of the effectiveness of this approach is uncertain.
Description of the intervention
Interventions developed and disseminated by guideline producers
to improve the consistent use of CPGs by health professionals and
health system managers include learning modules (which may be
accredited with Continuing Medical Education (CME) points),
education outreach visits (for example, academic detailing), com-
munication tools (for example, press releases following the publi-
cation of CPGs) or tailored formatting (for example, the wording
of recommendations adapted for a target audience or local health
system). Learning modules are a popular approach to support-
ing the use of CPGs; for example, NICE has developed a range
of online educational tools (NICE 2012b) in collaboration with
BMJ Learning, the Nursing Times and e-Learning for Health (for
example the eVTE online educational tool to reduce the risk of
venous thromboembolism (eVTE 2013)). The goal is to enable
users of CPGs to be more aware of recent evidence as summarised
in the relevant NICE guidance and to apply the newly acquired
knowledge in their practice and address any potential barriers. Ex-
amples of CPG producers working within health systems to im-
prove the uptake of their CPGs include: NICE working within
the National Health Service (NHS) in England andWales by pro-
viding commissioners with quality standards (NICE 2016); the
Scottish Intercollegiate Guidelines Network (SIGN) which pro-
vides problem-based small-group learning modules (SIGN 2012);
the American College of Cardiology providing a guideline clinical
app and running the Guidelines in Practice (GAP) project to pro-
vide customised, guideline-specific implementation tools (ACC
2016; Mehta 2002); the Veterans Health Administration adapt-
ing their CPGs for colorectal screening to local health organisa-
tions; Kaiser Permanente’s healthcare system which has developed
and implemented their Proactive Officer Encounter Programme
to provide clinical decision support to increase the uptake of their
own and other CPGs (Kanter 2010); and the National Prescrib-
ing Centre in the UK that set up the ’communities of practice’
(the NHS Medicines and prescribing communities of practice).
Data from NHS Evidence show that 92% (33/36) of guideline
producers submitting their CPGs for accreditation by NHS Ev-
idence publish support tools intended to aid implementation of
their guidance (NHS 2012a).Many guideline producers are work-
ing on transforming their narrative CPGs into electronic format,
as this may improve uptake through the implementation of CPGs
in computer-based decision-support systems (Peleg 2010).
How the intervention might work
Producers of CPGs who develop implementation interventions to
support their use have focused on the information needs of dif-
ferent user groups. Interventions are aimed at improving aware-
ness of CPGs, strengthening the skills needed to understand and
implement a CPG, and supporting the use of a CPG within the
context of a local healthcare system (Greenhalgh 2005). Tailoring
the implementation of interventions to facilitate practice change
(to promote a CPG) typically involves identification of the deter-
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minants of healthcare practice. This can include discussions with
healthcare professionals about potential barriers and systems re-
quiring change (Baker 2015), identification of ways to facilitate
change and designing, applying and assessing appropriate inter-
ventions (Wensing 2011). The Guideline Implementability Ap-
praisal (GLIA) instrument may be used by producers of guidelines
to identify barriers to implementation during the design phase of
a CPG and enable modifications prior to publication (Shiffman
2005). For example, templatesmay be developed for users of CPGs
to populate with local data in order to assess the applicability and
impact of a CPG. The tailoring process is also important in en-
gaging clinicians in the implementation process (Horbar 2004;
Titler 2009). Findings from a recent survey ofmore than 300NHS
commissioning staff, who use CPGs to guide decision making,
confirm the importance of these approaches. Local public health
intelligence, expert advice and examples of best practice appear to
be themost sought-after types of evidence, and in order for knowl-
edge to be used it has to be translated into a practical resource
(Gkeredakis 2011). Finally, if a guideline producer has authority
and works within the health system, or is perceived to be influen-
tial, the uptake of CPGs may be improved (Rogers 1995).
Other determinants of the effective implementation of all CPGs
are that they are clearly written, specific to a population and con-
text, easy to use and that there is research evidence of its effective-
ness for a particular end-user’s work context (Titler 2001). Guide-
line development is usually carried out by a multidisciplinary, na-
tionally-representative group, who conduct a systematic review to
identify and critically appraise the evidence, and who ensure that
the guideline recommendations are explicitly linked to the sup-
porting evidence. Expert opinions are also used in CPGs where
research evidence is not available. Producers of guidelines can also
use the AGREE tool by which the quality of a guideline may be
evaluated, thus allowing end-users to decide how well a guideline
has been developed and whether it will be applicable to the setting
in which they are working (AGREE 2010).
The format used to communicate the content of a CPG can also
influence its adoption (Greenhalgh 2005; Rogers 1995). While
CPGs are frequently written as text documents (Peleg 2010), stud-
ies have shown that clinicians usually do not use written guide-
lines during the actual care process (Wang 2002). Instead, patient-
specific advice, particularly if delivered during patient encounters,
is suggested to be more effective in changing clinician behaviour
(Shea 1996). Thus, implementing CPGs in computer-based de-
cision-support systems may improve the acceptance and appli-
cation of guidelines in daily practice, particularly if the actions
and observations of healthcare workers are monitored and advice
is generated whenever a guideline is not followed (Wang 2002).
One example of guideline producers who have provided healthcare
professionals with clinical decision support to increase the uptake
of CPGs is the Kaiser Permanente healthcare system with their
Proactive Officer Encounter Programme (Kanter 2010).
Gagliardi 2011 identified eight features of CPGs that are desired
by users of CPGs, or are associated with their use:
1. Usability: the structure of the CPG has been modified to
facilitate access, for example by providing a one-page summary
of the recommendations;
2. Adaptability: the CPG is available in different formats for
different users or purposes, for example, print and electronic
format, versions of the CPG are available for patients and
caregivers;
3. Validity: using a standardised system to grade the quality of
evidence supporting each recommendation, for example
GRADE;
4. Applicability: the wording of the CPG recommendation
has been tailored for different target audiences to support
application of the guidance to local circumstances; this may
include clinical and contextual information;
5. Communicability: information to supplement the CPG,
for example, educational resources for patients and information
to support patient involvement;
6. Accommodation: the addition of information on costs and
resources, for example, the costing templates provided by NICE,
and information on competencies and training required to
implement the recommendations;
7. Implementation: information on potential barriers and
strategies for facilitating implementation, for example, a clinical
assessment using a point-of-care template;
8. Evaluation: performance measures or quality indicators for
audit and monitoring.
Why it is important to do this review
CPGs can improve healthcare delivery and outcomes, but the
adoption of guidelines by clinicians and healthcare managers is
inconsistent. Previous Cochrane Reviews have described the ef-
fectiveness of a range of interventions to support the implemen-
tation of guidelines (Akl 2013; Flodgren 2011; Flodgren 2013a;
Forsetlund 2009; Giguère 2012; Grilli 2002; Jamtvedt 2006;
O’Brien 2007; Shojania 2009). However, most of these have been
developed independently of the producers of guidelines. Respond-
ing to continued concern about the inconsistent use of CPGs,
some national guideline producers have developed and imple-
mented tools to support the uptake of their CPGs. This is an addi-
tional investment for the guideline producer and the effectiveness
of this approach is not known. The focus of this review is to assess
the effectiveness of implementation tools, developed and dissem-
inated by guideline producers, on the uptake of their guidelines.
These tools may require changes to the presentation of the CPG
(e.g. tailoring of a CPG), or to be published alongside CPGs (e.g.
online learning modules).
O B J E C T I V E S
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To evaluate the effectiveness of implementation tools developed
and disseminated by guideline producers, which accompany or
follow the publication of a CPG, to promote uptake.
A secondary objective is to determine which approaches to guide-
line implementation are most effective.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We aimed to include randomised controlled trials (RCTs), cluster-
randomised trials (C-RCTs), controlled before-and-after studies
(CBAs) and interrupted time series (ITS) studies evaluating the
effects of guideline implementation tools developed by recognised
guideline producers to improve the uptake of their own guide-
lines. CBAs were eligible for inclusion if they involved at least two
intervention and two control sites, and ITS studies were eligible
if they had at least three data points before and three data points
after the intervention.
Types of participants
We included all qualified healthcare professionals, health system
managers and policy makers.
We excluded studies involving trainees or medical students.
Types of interventions
We included any interventions developed by producers of CPGs to
improve guideline implementation. Guideline producers include,
for example, theWorld HealthOrganisation (WHO), NICE, and
SIGN. As guidelines may be produced for a specific jurisdiction,
health system, or group of healthcare professionals, interventions
to improve the implementation of these CPGs may be distributed
to organisations but targeted at individuals within the organisa-
tion, or they may be targeted at entire organisations. We used the
definition of a CPG developed by the USA Institute of Medicine:
“clinical guidelines are systematically developed statements to as-
sist health care professional and patient decisions about appropri-
ate health care for specific clinical circumstances” (Field 1990).
Using the EPOC taxonomy (EPOC taxonomy 2002) as a guide,
we developed the following classification to organise and define
interventions as below:
1. Tools targeting the healthcare professional
i) Tailoring
• Tailoring of CPGs for different users to improve usability
and applicability: examples include using different wording,
varying the content, incorporating case studies of patients’
experiences in the form of vignettes or narratives which
contextualise the recommendations.
• Different CPG formats adapted for different users/
purposes, e.g. electronic (for use on a Personal Digital Assistant),
paper, multimedia versions, summaries, the inclusion of
algorithms.
ii) Education
• Learning modules (to include interactive learning modules)
which may be accredited with Continuing Medical Education
(CME) points, or to support the use of audit by junior doctors.
• Instructions/templates, e.g. instructions, tools or templates
to tailor guidelines/recommendations for local context (may also
be used at the organisational level); point-of-care templates/
forms (clinical assessment, standard orders).
• Decision-support systems, e.g. electronic guidelines with
built-in decision-support systems.
2. Tools targeting the patient
• Producing versions of CPG recommendations for the
public to improve provider-patient communication about
guideline recommendations.
3. Tools targeting the organisation of care
• Benchmarking tools, e.g. measures of gaps in performance
to be used by those monitoring the implementation of CPGs
(may also be used by individual healthcare professionals).
• Costing templates as a budgetary aid (may also be used by
individual healthcare professionals) to assess the resources
required to implement the CPG.
• Programme evaluation, audit tools, performance measures
and quality indicators to evaluate the implementation of the
CPG.
4. Mass media interventions
• Press releases following the publication of a CPG.
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The comparisons are as follows:
1. Tools developed by a guideline producer versus a tool
developed by another organisation or a guideline user (i.e. tools
developed independently of the CPG producer).
2. Tools developed by a guideline producer versus no tool (i.e.
CPGs alone).
We excluded the following types of studies/interventions:
1. Tools developed by groups of researchers, guideline groups
on commission (no longer existing).
2. Studies describing tools developed by guideline producers
to improve guideline uptake without providing objective
measurements of the effect of these interventions on professional
practice or patient outcomes.
3. Surveys of barriers/facilitators to the uptake of guidelines.
Types of outcome measures
We included studies reporting the following outcome measures:
Main outcomes
Objective measures of healthcare professional performance,
healthcare resource use or patient outcomes.
Secondary outcomes
Self-reportedmeasures of healthcare professional performance and
healthcare manager performance, including knowledge or use of
CPGs, and costs.
We excluded studies that only included self-reported outcomes.
Search methods for identification of studies
Electronic searches
Information specialist Nia Roberts (NR) developed the search
strategy for MEDLINE in consultation with the review authors,
and searched the Cochrane Database of Systematic Reviews and the
Database of Abstracts of Reviews of Effects (DARE) up toFebruary
2016 for related systematic reviews, and the following databases
for primary studies.
• Cochrane Effective Practice and Organisation of Care
(EPOC) Group Specialised Register, Reference Manager
• Cochrane Central Register of Controlled Trials
(CENTRAL) (Cochrane Library), Wiley (3 February 2016)
• NHS Economic Evaluation Database, HTA Database
(Cochrane Library), Wiley (3 February 2016)
• MEDLINE and MEDLINE In-Process and other non-
indexed citations, OvidSP (1946 to 3 February 2016)
• Embase, OvidSP (1974 to 3 February 2016)
• PsycINFO, OVIDSP (1967 to 3 February 2016)
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature), EbscoHost (1982 to 3 February 2016)
• Dissertations and Theses, ProQuest (3 February 2016)
• Index to Theses (up to 3 February 2016)
• Science Citation Index Expanded, ISI Web of Knowledge
(1945 to 3 February 2016)
• Conference Proceedings Citation Index - Science, ISI Web
of Knowledge (1990 to 3 February 2016)
• Health Management Information Consortium (HMIC),
NHS Evidence (1979 to 3 February 2016)
The MEDLINE search strategy (Appendix 1) was translated
for other databases using appropriate syntax and vocabulary for
those databases. The strategy included Medical Subject Headings
(MeSH) and synonyms for guidelines and implementation. Re-
sults were limited by two methodological filters: the Cochrane
Highly Sensitive Search Strategy (sensitivity- and precision-max-
imising version, 2008 revision) to identify randomised trials, and
anEPOCmethodology filter to identify non-RCTdesigns.Wedid
not apply language or publication status restrictions. Search strate-
gies for the other databases are found in Appendix 2; Appendix 3;
Appendix 4; Appendix 5; Appendix 6; Appendix 7; Appendix 8;
Appendix 9.
Searching other resources
We searched the following additional sources:
Grey literature
We conducted a ’grey literature’ search to identify studies not
indexed in the databases listed above. Sources included the sites
listed in Appendix 10. We document guideline websites searched
in Appendix 11.
Trial registries
We searched the following registries:
• International Clinical Trials Registry Platform (ICTRP),
Word Health Organization (WHO) (www.who.int/ictrp/en/)
• ClinicalTrials.gov, US National Institutes of Health (NIH)
(clinicaltrials.gov/)
We also :
• reviewed reference lists of all included studies, relevant
systematic reviews/primary studies/other publications;
• contacted authors of relevant studies or reviews to clarify
reported published information/seek unpublished results/data;
• contacted researchers with expertise relevant to the review
topic/EPOC interventions, as well as guideline-producing bodies
regarding any further published or unpublished research;
• conducted cited reference searches for all included studies
in ISI Web of Knowledge.
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Data collection and analysis
Selection of studies
We downloaded all titles and abstracts retrieved by electronic
searching to the reference management database Endnote (
EndNote X7) and removed duplicates. Four review authors (from
GF, AH, LG, SS) and an additional systematic reviewer indepen-
dently examined the remaining references, excluded those studies
which clearly did not meet the inclusion criteria, and produced a
long list of possible included studies. Two review authors (fromGF,
AH and SS) scrutinised these citations, obtained full-text copies
of potentially relevant references, and independently assessed the
eligibility of the retrieved full-text papers. We resolved disagree-
ments by discussion among review authors.
Data extraction and management
Two review authors (from GF, AH and LG) independently ex-
tracted data from each study into a modified EPOC data extrac-
tion form.We resolved disagreements by discussion among review
authors.We extracted the following information: setting; location;
characteristics of healthcare professionals; type of healthcare or-
ganisation; intended population of guideline; type and target of
intervention; the components of the intervention; the compari-
son intervention; any information about the time (and resources)
needed to implement or use the tool, or both; costs and outcomes
reported.
We also extracted data on any collaborative effort between pro-
ducers and users of guidelines aiming to improve the development
of implementation tools, e.g. engagement of individual healthcare
professionals or the organisation of care or both in the develop-
ment; assessment of barriers/facilitators to CPG adoption at the
provider level or at the organisational level, or both; or assessment
of the healthcare professionals’ or the organisation of care’s readi-
ness to change.
We used the Review Manager 5 software developed by Cochrane
(Review Manager 2014) to structure the content of the review
when writing it up for publication.
Assessment of risk of bias in included studies
Two review authors (from GF, AH, and LG) independently as-
sessed the risk of bias of each included study using the Cochrane’s
’Risk of bias’ tool (Higgins 2011) on six standard criteria:
1. Adequate sequence generation;
2. Adequate concealment of allocation;
3. Blinded or objective assessment of main outcome(s);
4. Adequately addressed incomplete outcome data;
5. Free from selective outcome reporting;
6. Free from other potential sources of bias.
We used four additional criteria specified by EPOC (EPOC2015):
1. Similar baseline characteristics;
2. Similar baseline outcome measures;
3. Reliable main outcome measures;
4. Adequate protection against contamination.
We resolved disagreements by discussion among review authors.
We assigned an overall assessment of the risk of bias (high, mod-
erate or low risk of bias) to each of the included studies using the
approach suggested in Chapter 8 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We considered
studies with low risk of bias for all key domains, or where it seems
unlikely that bias seriously alter the results, to have a low risk of
bias. We rated studies as high risk of bias if at least one domain
was unclear or studies were judged to have some bias that could
plausibly raise doubts about the conclusions as being at moderate
risk of bias. We considered studies with a high risk of bias in at
least one domain or judged to have serious bias that decreases the
certainty of the conclusions, to have a high risk of bias.
Measures of treatment effect
For each study, we reported data in natural units. Where baseline
results were available fromRCTs we reported pre-intervention and
postintervention means or proportions for both study and control
groups. We also calculated the absolute risk difference (ARD) for
each reported dichotomous outcome, using baseline data when
available.
Unit of analysis issues
There were no unit of analysis issues, all studies adjusted for clus-
tering (Bekkering 2005; Daucourt 2003; Fine 2003; Shah 2014).
Dealing with missing data
We did not contact authors to request missing data, for example,
when the main outcome was graphically presented without nu-
merical data.
Assessment of heterogeneity
Due to the heterogeneity between studies in terms of populations,
clinical conditions/targeted behaviour, and implementation tools
used,meta-analysiswas not feasible, andwe therefore did not assess
statistical heterogeneity.
Assessment of reporting biases
As meta-analysis of main outcomes was not feasible, we did not
assess publication bias through a funnel plot. However, our search
for studies to include was extensive and covered a number of guide-
line web sites, Guideline Clearing Houses and professional asso-
ciations.
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Data synthesis
As we did not find sufficiently homogeneous studies to permit
meta-analysis, we reported, for dichotomous outcomes, the me-
dian of medians of effect sizes across studies, as has previously been
done in other reviews (Flodgren 2011: Grimshaw 2004; Shojania
2009). When multiple adherence outcomes were reported within
individual studies, we first calculated themedian effect size (range)
across all outcomes reported in each study, and then calculated the
median of medians and interquartile range (IQR) across studies.
Two review authors used the GRADE tool
(www.gradeworkinggroup.org/) to judge the overall certainty of
the evidence for each outcome, using the following domains: risk
of bias, inconsistency, imprecision, indirectness and publication
bias. We downgraded the evidence for serious concerns about each
of these domains. We resolved disagreements through discussions
among the review authors. We presented the grading of the evi-
dence in Summary of findings for the main comparison.
Subgroup analysis and investigation of heterogeneity
As all of the included studies used implementation tools that tar-
geted the healthcare professional, and only one study targeted both
the healthcare professional and the patient, we did not undertake
any subgroup analyses.
Sensitivity analysis
We did not perform a sensitivity analysis, as no meta-analysis was
conducted.
R E S U L T S
Description of studies
Results of the search
See Characteristics of included studies; Characteristics of ongoing
studies and Characteristics of studies awaiting classification tables.
The electronic searches yielded 47,181 citations, down to 26,384
after removal of duplicates. Additional sources searched (includ-
ing websites and reference lists) yielded 473 citations. Of the
these 26,857 citations, we excluded 25,801 irrelevant studies and
retrieved and scrutinised 1,056 studies. Of these 1,056 double-
screened studies we excluded 1030 studies and added 14 to the
excluded studies table. We listed one study protocol and one
conference abstract under ’Ongoing studies’ (Salbach 2014; Te
Boveldt 2011), and two studies under ’Studies awaiting classifica-
tion’ (Maximov 2012; Van Driel 2007). We judged four studies to
be eligible for inclusion in the review. See study flowchart Figure
1.
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Figure 1. Study flow diagram.
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Included studies
We identified four eligible studies of cluster-RCTs (Bekkering
2005; Daucourt 2003; Fine 2003; Shah 2014) for inclusion in
this review, of which one (Shah 2014) consisted of two separate
cluster-RCTs: one a population-based C-RCT including all family
practices in Ontario, Canada, and the other an embedded C-RCT
including a subsample of the family practices from the larger study.
Populations
Healthcare professionals
In Bekkering 2005 the participants were physiotherapists (n =
113); and in two studies (Daucourt 2003; Fine 2003) the par-
ticipants were physicians other than general practitioners (GPs)
(n = 1913), or family physicians (number not reported), and in
one study the intervention was targeted at family physicians (Shah
2014). None of the studies targeted patients, health system man-
agers or policy makers.
Patients
The number and clinical condition of participants in the included
studies were as follows: participants (n = 500) with non-specific
low back pain (Bekkering 2005); participants (n = 608) with hos-
pital-acquired pneumonia (Fine 2003); an unknown number of
patients who required a thyroid-function test (Daucourt 2003);
and people with diabetes > 40 years old (n = 933,769) in Ontario
(administrative study) and a subgroup of people with diabetes (n
= 1592) at high risk of cardiovascular disease (clinical study) (Shah
2014).
Settings
Bekkering 2005 was set in private physiotherapy practices (n = 68);
two studies (Daucourt 2003; Fine 2003) were set in hospitals (n =
13), and Shah 2014 was set in family practices (n = 4007 and n =
80 respectively). The studies were conducted in the Netherlands
(Bekkering 2005), France (Daucourt 2003), the USA (Fine 2003)
and in Canada (Shah 2014) .
Targeted behaviour
The clinical conditions/behaviours targeted by the CPG were as
follows: care for peoplewith non-specific lowback pain (Bekkering
2005); appropriate thyroid-test ordering (Daucourt 2003); timely
conversion (and discharge) from intravenous antibiotic therapy to
oral antibiotics for people with pneumonia (Fine 2003); and im-
proved cardiovascular risk screening and risk reduction in people
with diabetes (Shah 2014).
The guideline recommendations (n = 4) that were implemented
were described in one of the studies (Bekkering 2005).
Guideline producers
See Table 1 for details on the guideline development process.
In Bekkering 2005 the Royal Dutch Physiotherapy Association
developed the guidelines; in Daucourt 2003 the Committee
for Co-ordinating Clinical Evaluation and Quality in Aquitaine
(CCECQA) developed the guidelines, together with regional
groups and national guideline developers; in Fine 2003 mem-
bers of the Pneumonia Patient Outcomes Research Team (PORT)
project developed the guidelines; and in Shah 2014 the Canadian
Diabetes Association (CDA) developed the guidelines.
Description of the intervention
See Table 2 , and Table 3.
i) Interventions targeting the healthcare professional
All four studies evaluated guideline implementation tools targeting
the healthcare professional.
Tailored interventions
Bekkering 2005 assessed the effectiveness of two (2½ hours) ed-
ucational training sessions for groups of 8 to 12 physiotherapists
on adherence to CPGs for management of non-specific low back
pain. The sessions were based on interventions reported as being
effective in the literature (e.g. interactive education and discussion,
feedback, and reminders) and were tailored to barriers found in a
survey.
Printed materials
Three studies evaluated the effectiveness of paper-based educa-
tional materials or reminders, or both (Daucourt 2003; Fine 2003;
Shah 2014).
Daucourt 2003 evaluated the combined effect of two tools: amem-
orandum pocket card and a test request form to implement guide-
lines for appropriate thyroid-test ordering. Orders were made by
checking a box, with boxes corresponding to inappropriate test
ordering shaded and therefore making ordering impossible.The
physician could overrule this by writing the order at the bottom
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of the sheet. The pocket card summarised the recommendations
according to the various clinical or therapeutic situations requiring
a thyroid test.
In Fine 2003 physicians received a multifaceted guideline inter-
vention which included placement of a detail sheet in the patient’s
medical record once a patient met guideline criteria for stability
when receiving intravenous antibiotic therapy for pneumonia, a
follow-up recommendation to the attending physician, and an of-
fer to arrange follow-up home nursing care. The three site-specific
detail sheets promoted any of three recommended action(s), i.e.
conversion from intravenous to oral antibiotic therapy only, con-
version and hospital discharge, or hospital discharge only.
Shah 2014 used a cardiovascular disease toolkit which was a col-
lection of printed educational materials, packaged in a brightly-
coloured box with CDA branding, sent to Canadian family physi-
cians. The contents included an introductory letter from theChair
of the practice guidelines’ Dissemination and Implementation
Committee; an eight-page summary of selected sections of the
practice guidelines targeted towards family physicians; a four-page
synopsis of the key guideline elements pertaining to cardiovascular
disease risk; a small double-sided laminated card with a simplified
algorithm for cardiovascular risk assessment, vascular protection
strategies, and screening for cardiovascular disease; and a pad of
tear-off sheets for patients with a cardiovascular risk self-assess-
ment tool and a list of recommended risk reduction strategies.
The median duration that an intervention was delivered was 22
weeks (range 4 weeks to 12 months).
ii) Interventions targeting the patient
None of the included studies evaluated interventions that targeted
the patient.
iii) Interventions targeting the organisation of care
None of the included studies evaluated interventions that exclu-
sively targeted the organisation of care.
iv) Interventions targeting the healthcare professionals and
the patients
None of the included studies evaluated targeted both healthcare
professionals and patients.
Assessment of barriers
In one of the three included studies (Bekkering 2005), barriers to
guideline implementation were assessed through the means of a
survey to inform the shape and content (i.e. tailoring) of the guide-
line implementation strategies. Another aim of the survey was to
retrieve information on themost important discrepancies between
current practice and recommendations of the guidelines. A model
for changing professionals’ behaviour and systematic reviews on
the effectiveness of implementation interventions was also used to
determine the content of the implementation strategy.
Theory base of interventions
None of the interventions used in the included studies was theory-
based.
Evidence base of interventions
The implementation strategies used in the included studies were
all supported by some evidence of their effectiveness and cited
high-quality Cochrane Reviews, systematic reviews or overviews
to justify their choice of strategies.
Fidelity
None of the included studies provided information on interven-
tion fidelity.
Delivery of the intervention
Mode of delivery:
In Bekkering 2005 the intervention was delivered face-to-face. In
two studies (Daucourt 2003; Shah 2014) the paper-based inter-
ventions were provided passively. In Fine 2003 one part of the
intervention was delivered over the phone, and the rest passively
in the form of paper-based materials.
Provider delivering the intervention (if not electronic, paper-
based, etc):
In Bekkering 2005 the principal investigator and two additional
trainers delivered the intervention. In Fine 2003 a nurse delivered
part of the intervention.
Comparison interventions
The comparison intervention in all included studies was passive
guideline dissemination. Additional material that was delivered
together with the guideline was as follows: in Bekkering 2005 four
forms: a self-evaluation form to assess whether their current man-
agement was consistent with the recommendations contained in
the clinical guidelines, two forms facilitating discussion with other
physiotherapists and general practitioners respectively, a copy of
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the Quebec Back Pain Disability Scale, and a summary of the
CPG. In Fine 2003 a cover letter was sent signed by the hospital’s
utilisation management director describing the rationale for the
guideline. In Daucourt 2003 all physicians were invited to a local
information meeting. In Shah 2014 control participants received
the CDA newsletter, which included the revised guideline.
Outcomes
Healthcare professional outcomes
Two of the four included studies reported a measure of healthcare
professional adherence to guidelines (Bekkering 2005; Daucourt
2003) at four weeks; these were included in the calculations of the
median absolute risk difference (ARD).
Healthcare resource use and costs
Fine 2003 reported length of initial hospital stay and re-admissions
at 30days after indexhospitalisation. Shah 2014 reported (primary
outcome in clinical study) the proportion of patients with diabetes
at high risk of a cardiovascular event who were prescribed a statin
(see Table 4 for details on secondary outcomes reported).
Two studies reported on costs (Bekkering 2005; Saillour-Glénisson
2005 (belonging to Daucourt 2003)). One of the studies reported
mean annual cost per patient, total cost for releasing the guideline
and cost of active implementation intervention (Bekkering 2005).
The other article awaits translation (Saillour-Glénisson 2005).
Patient outcomes
Bekkering 2005 reported quality-of-life measures at four weeks.
Fine 2003 reported all-cause and pneumonia-related mortality,
medical complications, functional status and patient satisfaction
with care at 30 days after the initial hospitalisation. Shah 2014
reported (primary outcome in administrative data study) death
or non-fatal myocardial infarction. Daucourt 2003 reported the
number of requests for a thyroid function test that complied with
the guidelines (Guideline Conformity Rate (GCR)) at 4 weeks.
(See Table 4 for details of the secondary outcomes reported).
Excluded studies
After scrutinising the full text we excluded 1030 studies and added
14 to the excluded studies table. See Characteristics of excluded
studies table.
Risk of bias in included studies
See ’Risk of bias’ tables within the Characteristics of included
studies, Figure 2 and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study. White space indicate studies not reporting non-objective outcomes and for which risk of bias could not
be assessed.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies. White spcace indicate studies not reporting non-objective outcomes
and for which risk of bias could not be assessed.
The randomisation sequence and the allocation concealment were
adequate in three studies (Bekkering 2005; Daucourt 2003; Shah
2014), and unclear in Fine 2003. In Shah 2014 blinding was ad-
equate (clinical data study assessed), and in Daucourt 2003 it was
unclear whether or not the healthcare professionals were blinded,
while in two studies (Bekkering 2005; Fine 2003) it was clear that
they were not. In one study the healthcare professional selected a
maximum of 10 consecutive patients for the study, and we there-
fore judged the risk of performance bias to be high (Bekkering
2005). Performance bias was also judged high in Fine 2003 as
treatment assignment was not concealed. Blinding of outcome
assessment was adequate in two studies (Bekkering 2005; Shah
2014), and unclear in the other two. Baseline characteristics were
reported to be similar in one study (Fine 2003), not similar in
one study (Shah 2014), and unclear in the other two studies. The
outcome data were complete in two studies (Daucourt 2003; Shah
2014), and unclear in the other two (with losses to follow-up of
more than 20%). In Shah 2014 some of the outcomes that were
listed in the trial protocol were not in the study report, while in
the other three studies the risk of selective reporting was low. Shah
2014 had unclear risk of other bias (contamination), while the
other three were at low risk.
Effects of interventions
See: Summary of findings for the main comparison
i) Interventions targeting the health care professionals
Healthcare professional outcomes
See Summary of findings for the main comparison; Table 4 and
Table 5.
Two of the four included studies (Bekkering 2005; Daucourt
2003) reported one or more measures of healthcare professionals’
adherence to guidelines. The overall median absolute risk differ-
ence (range) (five comparisons) was (range: 0.115 to 0.159), i.e. a
median difference in adherence of 13.5%, with the effects ranging
from 11.5% to 15.9% increase in adherence.
Fine 2003, in which physicians received an educational mailing,
a daily assessment of (pneumonia) patient stability and an addi-
tional sheet to the medical notes with a follow-up recommenda-
tion for converting from intravenous to oral antibiotic and hospital
discharge, compared with education mailing alone, reported that
those in the intervention group had a more rapid rate of conver-
sion to oral antibiotics (hazard ratio (HR) 1.23, 95% confidence
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interval (CI) 1.00 to 1.52, P = 0.06). Shah 2014 did not report
health professional outcomes.
Healthcare resource use and costs
Fine 2003 reported similar percentages in each group of patients
being readmitted (intervention group 14% versus 11% in the con-
trol group), and a similar length of initial hospital stay (median of
five days in each group) at 30 days after index visit.
Shah 2014 reported similar or slightly lower (= undesired effect)
use of different types of coronary artery disease (CAD) assessment
tools in practices that received the guideline tool compared to
those who received the updated guideline only (administrative
data study), as was the case for the medication initiation outcomes
(both were secondary outcomes).
Bekkering 2005 reportedmean annual direct medical costs for the
intervention group of EUR 374 versus EUR 449 in the control
group. Direct costs included costs of the dissemination of the
guideline and healthcare resource use by the patient. Daucourt
2003 reported prescribing cost data in a paper in French (Saillour-
Glénisson 2001) which awaits translation.
Patient outcomes
See Table 4 for details
Bekkering 2005 reported similar quality-of-life scores for patients
with non-specific low back pain at 12 months.
Fine 2003 reported similar scores on the SF-12 physical compo-
nent score (intervention group 45 (standard deviation (SD) 7)
versus control group 45 (SD 7)) and the mental component score
(intervention group 45 (SD 6) versus control group 45 (SD 7)) at
30 days after index stay, and little or no difference for mortality
(intervention group 8% versus control group 9%), and return to
work (HR 0.99, 95%CI 0.63 to 1.58). The same authors reported
fewer hospital complications in the intervention group compared
with control (157 (55%) and 206 (63%) respectively, P = 0.04).
Shah 2014 reported little or no difference between groups (Inter-
vention 2.5%; Control 2.5%; odds ratio (OR) 1.00, 95% CI 0.96
to 1.03, P = 0.77) for death and non-fatal myocardial infarction
(primary outcome in the administrative data study), and also little
or no difference for any of the other (secondary) clinical events
reported (see Table 4 for details).
ii) Interventions targeting the organisation of care
No studies reported results for this comparison.
iii) Interventions targeting the patient
No studies reported results for this comparison.
iv) Interventions targeting the healthcare professional, the
organisation of care and/or the patient
No study reported results for this comparison.
Effectiveness of different approaches of guideline
dissemination
We include four studies in this review, of which one evaluated the
effectiveness of two short tailored educational workshops, and the
other three studied the effects of using paper-based tools, includ-
ing order forms or reminders, or both. As the types of multifaceted
interventions, the clinical condition and behaviour targeted varied
across studies it was not possible to determine which of the dif-
ferent approaches used to improve implementation of guidelines
was most effective.
D I S C U S S I O N
Summary of main results
We identified four eligible cluster-RCTs for inclusion in this re-
view, evaluating the effects of tools developed by existing guideline
producers to improve implementation of their guidelines.
All included studies evaluated tools that targeted the healthcare
professional. However, meta-analysis was not feasible, since the
targeted clinical conditions and behaviour, as well as the guideline
tools used, all varied between studies. The variation in the duration
of interventions and follow-up also made comparisons difficult.
Tools developed by guideline producers, and given to healthcare
professionals as an aid to improve compliance, probably lead to
greater adherence to guidelines (median absolute risk difference
(ARD) 13.5%) at an average four weeks follow-up (moderate-
quality evidence). The effect ranged from11.5% in one study (two
tailored short educational workshops to improve management of
non-specific low back pain) to 15.9% in the other (a pocket mem-
orandum card and test-request form to improve thyroid-test order-
ing). Neither study reported baseline adherence, and it appeared
that no guideline for the specific targeted behaviours and condi-
tions was previously in place. There was low certainty of evidence
from one trial for little or no difference in costs between groups.
Due to the few eligible studies identified, and the variety of inter-
ventions implemented, we could not determine which approaches
are most effective, which was the secondary objective of this re-
view. Two of the included studies reported on cost data, and one
of these awaits translation. While it is not possible to directly ad-
dress the investment made by guideline producers in developing
implementation tools, the cost is not likely to differ substantially
from other organisations that develop tools to support the im-
plementation of guidelines. It should be noted that even small to
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moderate intervention effects may be highly cost-effective if the
targeted clinical condition is highly prevalent and the implemen-
tation tools used are inexpensive to develop and to disseminate.
There is no evidence available for the effectiveness of interventions
targeting the organisation of care or the patient.
Overall completeness and applicability of
evidence
In all included studies the interventions targeted the healthcare
professional. None of the included studies used tools that targeted
health systemmanagers or policy makers, the patient (e.g. versions
of the guideline developed for the patient), or the organisation of
care (e.g. benchmarking tools, costing templates or programme
evaluation, audit tools, performance measures and quality indica-
tors to evaluate the implementation of the CPG), and no study
evaluated the effects of mass media interventions. The implemen-
tation tools used were delivered alongside the CPG, and none was
imbedded within the CPG (e.g. tailoring of the CPG for a specific
audience). In addition, only guideline tools to promote the use
of CPGs for a few clinical conditions and behaviours have been
evaluated.
Quality of the evidence
The evidence was from cluster-RCTs that had all taken clustering
into account in the analysis. We downgraded all included studies
from high tomoderate certainty of evidence for themain outcome
(adherence to guidelines), due to high risk of bias. As only a single
study provided evidence for the effectiveness of a certain imple-
mentation on costs, our confidence in the evidence was further
downgraded to low due to imprecision.
Potential biases in the review process
We searched a large number of databases using a strategy that was
designed by a senior information specialist, and then adapted for
different databases. We also searched a large number of websites of
relevant guideline producers. Four review authors sifted a number
of references identified by the electronic searches, excluding papers
that were irrelevant and clearly not eligible, and producing a long
list for a second review author to go through. Two review authors
independently assessed all potentially eligible titles and abstracts
against the eligibility criteria to ensure no important references
were missed. We also performed data extraction and assessment of
risk of bias in duplicate.
Agreements and disagreements with other
studies or reviews
We are not aware of any other reviews that have evaluated the
effectiveness of tools developed by recognised guideline produc-
ers to improve implementation of their own CPGs. However, our
results of a median 13.5% greater adherence to guidelines in the
intervention group (two studies: one evaluating a paper-based in-
tervention, and one an intervention consisting of two short ed-
ucational workshops) are greater than the reported median ab-
solute improvement in performance for point-of-care computer
reminders of around 4% (Shojania 2009), 2% for printed edu-
cational materials (Giguère 2012) and 6% for educational meet-
ings (Forsetlund 2009). These reviews, however, included a much
larger number of studies and participants, which may explain the
differences in effect.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is a range of guideline tools that guideline producers could
develop. However, for tools developed by large guideline-produc-
ing bodies, there is limited evidence about their effectiveness. It is
difficult to draw robust conclusions about the tools evaluated in
our review, given the small number of studies and heterogeneity
in study conditions, interventions, and outcomes.
Implications for research
Given that many CPG developers are providing tools to support
implementation, they should consider embedding rigorous evalu-
ations of the tools (e.g. randomised trials) to advance knowledge
in this area. They should also aim to include economic analyses to
determine the cost effectiveness of their tools.
Future studies in this area should also aim to:
• study the effect of organisational interventions, patient
interventions, and of tools embedded in a guideline (e.g.
tailoring of the content to specific audiences) using a randomised
comparison
• use validated objective measures of adherence to guidelines
and longer follow-up
• report numerical data to accompany graphical figures
• describe the process of developing the guideline and the
implementation tool, including any theory used, the evidence
base for the intervention
• provide information on who developed the guidelines, and
the guideline development process, as well as describing the
number and complexity of the guideline recommendations
• provide information on who delivered the intervention (the
study authors, independent personnel, etc.), and detailed
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information on the intensity of interventions (number of face-to-
face contacts, contact time, etc.) to permit replication and
comparison with other studies
• use the TIDieR checklist (Hoffman 2014) to improve the
reporting of the characteristics of an intervention
• conduct an economic evaluation, taking into account the
development of the guideline, and the dissemination and
implementation of the guideline.
.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bekkering 2005
Methods Study design: Cluster-RCT
Unit of allocation: The physiotherapy practice
Guideline development: The guidelines used the Dutch method of developing physio-
therapy guidelines, and evidence from systematic reviews was sought and used as the basis
for the recommendations. If no evidence was available, consensus between experts was
obtained.The guidelines were pilot-tested among 100 physiotherapists and reviewed by
an external multidisciplinary panel. A survey, to assess barriers, was part of the guideline
development process
Guideline implementation tool development: The face-to-face training sessions were
based on interventions that have all been shown to be effective (see below). The content
of the strategy was determined on the basis of information about the expected barriers for
implementation gathered during the development of the clinical guidelines. Two experts
gave advice on the content of the strategy
Theories used: The authors did not reporting using theory to guide the development
of the intervention; they based their intervention on implementation methods known
to be effective (interactive education and discussion, feedback, and reminders)
Sample size calculation: The calculation of sample size was based on a difference of 20%
in adherence between the 2 groups, which was considered to be an important difference.
It was adjusted for the effect of clustering using an ICC of 0.057 and an estimated cluster
size of 5 patients per practice. In total, a sample of 284 patients or 48 practices or both
were needed (2-sided α = 0.05, β = 0.20)
Participants Participating providers: Physiotherapists n = 68 practices (113 physiotherapists); In-
tervention: n = 34 practices (52 physiotherapists); Control: n = 34 practices (61 phys-
iotherapists); 325/6261 = 5.2% of all eligible practices were selected to be invited to
participate, of which 257 practices declined participation (79.1%)
Losses to follow-up and withdrawals: 6 physiotherapists (4 from the intervention
group and 2 from the control group) dropped out immediately after randomisation;
these were more often working in a solo/duo practice (P = 0.038). 9 physiotherapists
from the intervention group did not complete training, and 11 participants also from
intervention group (3 did not complete registration, 8 did not include any patients) and
11 participants from the control group (who did not include any patients) were lost to
follow-up
Characteristics of healthcare professionals:
Mean (SD) experience (years): Intervention: 15.7 (8.8); Control: 14.1 (8.3)
n (%) postgraduate education on low back pain: Intervention: 36 (75.0%); Control: 41
(69.5%)
n (%) postgraduate education on chronic pain: Intervention: 0 (0%); Control: 4 (6.8%)
Patients:patients (n = 500) with non-specific low back pain
Setting: private physiotherapy practices; n =113 physiotherapists.
Location (rural/urban): Central part of the Netherlands
Country: The Netherlands
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Bekkering 2005 (Continued)
Interventions Aims: To evaluate the effect on the process of care of an active strategy to implement
clinical guidelines on physiotherapy for low back pain
Type of intervention: Intervention targeting the healthcare professional (educational
intervention/tailoring)
Description of guideline tool: An active strategy to implement the CPGs which con-
sisted of 2 training sessions, each lasting 2½ hours, for groups of 8 - 12 physiothera-
pists. For each session a preparation time of 2 hours was recommended. The sessions
were based on interventions shown to be effective, such as interactive education and
discussion, feedback and reminders.The content of the strategy was determined on the
basis of information about the expected barriers for implementation gathered during
the development of the clinical guidelines.Two experts gave advice on the content of the
strategy
Guideline developers:Royal Dutch Physiotherapy Association (National Physiotherapy
guidelines)
Delivery: Postal delivery of guideline; small-group face-to-face training and reminders;
By whom: The primary investigator and 1 of 2 additional trainers with adequate clinical
experience in the management of low back pain supervised the training sessions
Timing: The guideline was published in 2001, and the study was conducted between
May 2001 and December 2002
Duration of intervention: 2 X 2½ hours (+ 2 hours recommended preparation time),
4 weeks between the first and the second session
Control: All physiotherapists received the clinical guidelines via the standard method
of dissemination (by mail) used by the Royal Dutch Society for Physiotherapy. They
received the guidelines by mail together with 4 forms: a self-evaluation form to assess
whether their current management was consistent with the recommendations contained
in the clinical guidelines, 2 forms facilitating discussion with other physiotherapists and
general practitioners respectively, and a copy of the Quebec Back Pain Disability Scale. A
summary of the clinical guidelines was also provided. At the same time an article about
the development of the guidelines was published in a Dutch professional journal for
physiotherapists
Outcomes Main outcome:
• Adherence to the guidelines
Secondary outcome:
• Costs (reported in Hoeijenbos 2005)
• Quality of life (assessed with the EQ-05 and reported in Hoeijenbos 2005)
Follow-up: 4 weeks after randomisation (adherence outcomes), 12 months (cost out-
comes)
Notes Ethical approval and informed consent obtained (yes/no): Yes
Conflict of interest: None declared
Funding: the Ministry of Health, Welfare and Sports
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk p. 108, Col. 1, Para. 2
”Block randomisation (blocks of four prac-
tices) was carried out after pre-stratification
for the work setting (solo/duo practices ver-
sus group practices). A statistician, whowas
not involved in this trial, drew up an allo-
cation schedule using a computerised ran-
dom number generator.“
Allocation concealment (selection bias) Low risk The primary investigator (GEB), without
any knowledge of the practices, listed the
practices alphabetically according to the
name of their street address, and subse-
quently assigned them to the intervention
or control group using the allocation sched-
ule
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Outcome group: adherence to guidelines
The participating physiotherapists could
not be blinded to the intervention. The
physiotherapist selected a maximum of 10
consecutive patients for the study.High risk
for performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk p.108, Col.1, Para.5
“Two reviewers independently assessed the
registration form using the algorithm with-
out being aware of the group allocation. In
total, four reviewers assessed the forms. Be-
fore the final scoring five cases were used for
a pilot assessment and these were blinded
again afterwards. In case of disagreement
between the two reviewers, a method was
used to discuss and resolve the disagree-
ment by consensus. If the disagreement
persisted, a third reviewer made the final
decision.”
Baseline characteristics similar Unclear risk Physiotherapists in the intervention group
were slightly older (P = 0.011), but there
were no other differences between the 2
groups. 500 patients were included
Baseline outcome measures similar Unclear risk The intervention group had a higher qual-
ity-of-life score, 0.6730 (SD 0.2042) com-
pared with the control group 0.6134 (SD
0.2661)
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Incomplete outcome data (attrition bias)
All outcomes
High risk 37/52 intervention physiotherapists (71.
2%) and 48/61 control physiotherapists
(78.7%) remained in the study at follow-
up
Selective reporting (reporting bias) Low risk Results reported for all outcomes listed in
the Methods section
Other bias Low risk No evidence of other risk of bias
Daucourt 2003
Methods Study design: Cluster-RCT
Unit of allocation: The wards
Guideline development: The CCECQA established the guidelines in collaboration
with a regional working group and a national review group. The method combined a
comprehensive review of the literature and expert consensus
Guideline implementation tool development: No information
Theories used: No information
Sample size calculation: The expected prevalence used for the sample size calculation
was the rate of test ordering of “TSH only.” With a probability of 0.05, an error of 0.20,
an expected rate of test ordering of “TSH only” in the control group of 0.50, a minimal
increase in test ordering of the “TSH only” rate of 0.10, an ICC of 0.25 and an estimated
average number of thyroid function tests by cluster (ward) of 40
Participants Participating healthcare professionals: Physicians; n = 704; Intervention (Dual Inter-
vention Group): n = 346; Control Group (guideline only) n = 358). Note: 2 study arms
(Order Form Group, n = 339; Pocket Card Group, n = 369) were not included in this
review
Ward specialty
Medicine : Dual intervention: 63; Control: 76; Emergency: Dual intervention: 2; Con-
trol: 0; Psychiatry: Dual intervention: 34; Control: 24
Surgeon: Dual intervention: 1; Control: 0
Prescriber status
Senior: Dual intervention: 53; Control: 57; Junior: Dual intervention: 43; Control: 40;
Unknown: Dual intervention: 4; Control: 3
Indication of test ordering*
Test of thyroid dysfunction: Dual intervention: 61; Control (guideline only): 59
Therapeutic tests: Dual intervention: 23; Control (guideline only): 23
Other pathologic test: Dual intervention: 16; Control (guideline only): 18
Losses to follow-up and withdrawals: 52 tests were not accounted for
Patients: Patients with symptoms indicating a need for a thyroid function test
Setting: 6 volunteer general hospitals all receiving residents: 2 middle-sized hospitals in
the second and third largest towns in Aquitaine (Pau hospital (535 beds) and Bayonne
hospital (494 beds)), 2 small-sized hospitals (Bergerac hospital (171 beds) and Bouscat
hospital (90 beds)) and 2 psychiatric hospitals (Charles Perrens hospital (904 beds) and
Cadillac hospital (541 beds))
Location (rural/urban): Aquitaine, in South-West France
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Country: France
Interventions Aims: To compare the (independent) and combined effectiveness of 2 implementation
interventions (a memorandum pocket card and a test request form) of guidelines for
ordering thyroid function tests
Type of intervention: interventions targeting the healthcare professional
Type of guideline tool: a Memorandum Pocket Card (MPC) and a Test Request Form
(TRF).The TRF replaced the former order sheet. It was a 2-by-2 grid with coloured
boxes (white, grey, black). Orders were made by checking the box at the intersection
between test and clinical situations. Boxes corresponding to inappropriate test ordering
were shaded, therefore making ordering impossible.The physician could overrule this by
writing down the order at the bottom of the sheet. The MPC summarised the recom-
mendations according to the various clinical or therapeutic situations requiring thyroid
exploration. It was small enough for physicians to keep it in their coat pocket and to
consult it before prescribing thyroid function test
Guideline developers: The CCECQA established such guidelines in collaboration with
a regional working group and a national review group
Delivery: Paper-based interventions (and face-to-face meeting)
Timing: Unclear
Duration of intervention: 4 weeks
Control: Physicians in all groups received guidelines and were invited to a local infor-
mation meeting
Outcomes Main outcome:
• Proportion of thyroid function test ordering in accordance with the guidelines
(Guideline Conformity Rate (GCR))
Follow-up: 4 weeks after guideline implementation
Notes Ethical approval and informed consent obtained (yes/no): No information
Conflict of interest: No information
Funding: Supported in part by the AgenceNationale de l’Accreditation et de l’Evaluation
en Santé (ANAES)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk p. 433, Col. 2, Para. 1
“Randomization was performed by the
CCECQA using a random number table.”
Allocation concealment (selection bias) Low risk Cluster-RCT .
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Outcome group: proportion of thyroid-
function test ordering in accordance with
the guidelines
It was not explicitly stated if the health-
care professionals ordering the tests were
blinded to the intervention
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk p. 433, Col. 2, Para. 3
“A standardized collection grid was
prospectively filled in by a research assistant
in each hospital for all consecutive thyroid
function tests ordered during the collection
period. No information on blinding.”
Baseline characteristics similar Unclear risk Gender differed according to the interven-
tion groups: the proportion of women was
65% in the dual intervention group, 63%
in the order-form group, 73% in the pocket
card group and 61% in the control group
(P < 0.01). The mean patient age was 67
years (SD 20 years) in the dual interven-
tion group, 64 years (SD 20 years) in the
order-form group, 70 years (SD 21 years)
in the pocket card group, and 66 years (SD
17 years) in the control group (P < 0.01)
. No ward/healthcare professional charac-
teristics provided
Baseline outcome measures similar Unclear risk No baseline measure of outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Indication of test ordering unknown for 52
(3.1%) patients (total n = 1464)
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
Other bias Low risk No evidence of other risk of bias
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Methods Study design: Cluster-RCT
Unit of allocation: Groups of physicians
Guideline development:The medical practice guideline developed for this project was
based on a review of the evidence of the time to reach clinical stability, and consensus of
an 8-member national guideline panel. The guideline was reviewed by clinical opinion
leaders at each study site, and was approved for local use by the relevant utilisation
management department. The final guideline consisted of explicit clinical criteria to
define stability for conversion from intravenous to oral antibiotic therapy and for hospital
discharge
Guideline implementation tool development: No information
Theories used: No information
Sample size calculation:This study was designed with 80% power to detect a 1-day
decrease in length of stay from an assumed baseline of 7.2 days. The sample size was
adjusted for the clustering on physician group (22), assuming an average of 3.5 patients
per group and an ICC of 0.1
Participants Participating healthcare professionals: 116 groups of physicians who were likely to
treat patients with community-acquired pneumonia: Intervention: 277 physicians (57
groups); Control: 268 physicians (59 groups)
Characteristics of healthcare professionals:
Age (years): Intervention: 47 ± 11; Control: 46 ± 11, P = 0.35
Female: Intervention: 45 (18); Control: 57 (24) , P = 0.09
Medical specialty, P = 0.14
Generalists: Intervention: 190 (73); Control: 192 (79)
Pulmonary specialist: Intervention: 19 (7); Control: 19 (8)
Other specialists: Intervention: 50 (19); Control: 31 (13)
Patients: Patients treated by a participating physician and who had a documented treat-
ment plan for hospital-acquired pneumonia, and a chest radiograph report consistent
with a new pulmonary infiltrate; Intervention: n = 283; Control: n = 325. Note: only
40% of eligible patients were enrolled
Setting: 7 non-profit hospitals: 1 university teaching hospital (site A); 3 community
teaching hospitals (sites B,C and D); 3 community non-teaching hospitals (sites E.F and
G)
Location (rural/urban): Pittsburg, Pennsylvania
Country: USA
Interventions Aims: To determine whether implementation of an evidence-based guideline would
reduce the duration of intravenous antibiotic therapy and length of stay for patients
hospitalised with pneumonia
Type of intervention: Education (detail sheet with treatment recommendations)
Type of guideline tool: An educational mailing delivered to physicians and a daily as-
sessment of patient stability that was coupled with a multifaceted strategy to implement
the project guideline once a patient met criteria for stability. A detail sheet was placed
in the patient’s medical record once a patient met guideline criteria for stability, a fol-
low-up recommendation to the attending physician, and an offer to arrange follow-up
home nursing care. One of the 3 site-specific detail sheets promoting the recommended
action(s) (i.e. conversion from intravenous to oral antibiotic therapy only, conversion
and hospital discharge, or hospital discharge only) was placed in the physician progress
notes section of each patient’s chart immediately following the determination of the
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corresponding type(s) of stability. At this time, the research nurse telephoned or directly
approached the patient’s attending physician to state that the patient met guideline cri-
teria for conversion to oral antibiotic therapy or hospital discharge (or both); to indicate
that the detail sheet had been placed in the medical record and review its content with
the physician; and to offer to take a verbal order for oral antibiotic therapy and make
arrangements for home nursing care
Guideline developers: Researchers who were part of the PORT group
Delivery: Paper-based detail sheets/treatment recommendations; nurse telephone re-
minder
Timing: Once the patient treated with intravenous antibiotics had been deemed to be
in a stable condition according to the guidelines, the intervention tool was delivered.
The CPG was delivered as part of the educational mailing 1 month before recruitment
of patients started
Duration of intervention: 12months (patients were recruited between 1 February 1998
and 31 March 1999)
Control: The educational mailing was delivered to physicians in both study arms dur-
ing the month before patient recruitment began. The control group receive a practice
guideline alone. This mailing included a cover letter signed by the hospital’s utilisation
management director describing the rationale for the guideline and a written version of
the guideline
Outcomes Main outcomes:
• Duration of intravenous antibiotic therapy
• Length of index hospital stay
• Time to stability (for conversion to oral antibiotics and for discharge)
Secondary outcomes:
• All-cause mortality (data retrieved from records)
• Pneumonia-related mortality (data retrieved from registers)
• Medical complications (data retrieved from medical records)
• Rehospitalisation rates (interview assessed)
• Functional status (subgroup only, results not included in this review)
• Time to return to usual activities (subgroup only, results not included in this
review)
• Patient satisfaction with care
Follow-up: secondary outcomes were assessed 30 days after the index hospitalisation
Notes Ethical approval and informed consent obtained (yes/no): Yes
Conflict of interest: None declared
Funding: The Agency for Healthcare Research and Quality, Rockville, Maryland, and
the National Institute of Allergy and Infectious Diseases (HS08282), Bethesda, Mary-
land. Dr Fine was also supported in part as a Robert Wood Johnson Foundation Gener-
alist Physician Faculty Scholar and by a Career Development award from the National
Institute of Allergy and Infectious Diseases
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk No information
Allocation concealment (selection bias) Unclear risk The groups of physicians that were ran-
domised to intervention and control group
were at the same location
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Outcome group: duration of intravenous
antibiotic therapy
“ Because of the nature of the intervention,
physicians and research nurses could not
be blinded to their treatment assignments.
Patients were not informed of their physi-
cians’ treatment assignment”
Blinding of participants and personnel
(non-objective outcomes)
Unclear risk Outcome group: hospitalisations, func-
tional status
At the 30-day telephone interview, pa-
tients or their proxy respondents were
queried about subsequent hospitalisations
(patient self-report). Functional status was
reassessed with the SF-12 (18) for patient
respondents only
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome group: duration of intravenous
antibiotic therapy; length of stay for the
index hospitalisation. Data retrieved from
registers, but unclear by whom
Baseline characteristics similar Low risk Baseline characteristics similar (Table 2)
Baseline outcome measures similar Unclear risk No baseline measures of outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk There were 25 post-enrolment exclusions
(providers) in each study arm, and 10 in-
hospital study withdrawals (4 intervention
and 6 control)
Selective reporting (reporting bias) Low risk Results reported for all outcomes listed in
the Methods section
Other bias Low risk No evidence of other risk of bias
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Methods Study design: 2 separate studies: 1 a population-based multicentre cluster-RCT, and the
other an embedded C-RCT including a subgroup of these practices
Unit of allocation: family practices
Guideline development: Candadian Diabetes Association (CDA) updated their 2008
guideline: reviewed the literature and graded the evidence as well as the applicability of
evidence, and subjected the revised draft guideline to external peer review
Guideline implementation tool development: The CDA formed a Dissemination and
Implementation Committee to create a guideline implementation strategy. The first
component of this strategywas aimed at improving adherence with the recommendations
for cardiovascular disease screening and treatment for people with diabetes. The strategy
highlighted the identification of diabetic patients at high risk for cardiovascular events,
treatment targets and methods for vascular protection, and the selection of patients and
methods for coronary artery disease screening. The toolkit was created for the CDA
by clinical experts including family physicians, endocrinologists, and other healthcare
professionals, with guidance from clinicians with expertise in knowledge translation and
implementation
Theories used: the toolkit was developed without a specific quality improvement or
educational theory to guide its content or delivery
Sample size calculation: Administrative data study: an administrative data base of the
entire population aged ≥ 40 years with diagnosed diabetes in Ontario, which was more
than 900,000 people; the study had .95% power to detect an unadjusted absolute differ-
ence of at least 0.4% in a dichotomous primary outcome, using an α-error of 0.05. Power
was reduced after adjustment for baseline differences and for clustering, but remained
sufficient to detect very small differences in outcomes
Cinical data study: The sample size for the clinical data study was based on an absolute
10% difference in statin prescription rates between intervention and control patients,
a threshold similar to the median effect size found in a systematic review of printed
educational materials; with 80% power and an α-error of 0.05, a sample size of 796 per
group with 20 patients per practice was required
Participants Participating providers:
Administrative data study: all family practices in Ontario; Intervention: 2008 practices;
Control: 1999 practices, number of healthcare professionals not reported;
Cllincal data study: Intervention: 40 practices; Control: 40 practices
Practice type
Administrative data study: Solo: Intervention: 1125 (56.0); Control: 1155 (57.8); Group:
Intervention: 883 (44.0); Control: 844 (42.2)
Rural practice: Intervention:190 (9.5); Control:160 (8.0)
Diabetes patient volume:
< 100; Intervention: 760 (37.8), Control: 708 (35.4)
100 to < 200: Intervention: 742 (37.0), Control: 788 (39.4)
200+ : Intervention: 506 (25.2), Control: 503 (25.2)
Clinical data study:: Solo: Intervention: 16 (40.0), Control: 22 (55.0); Group: Interven-
tion: 24 (60.0), Control: 18 (45.0)
Rural practice ; Intervention: 2 (5.0), Control: 1 (2.5)
Diabetes patient volume
< 100; Intervention:7 (17.5), Control: 4 (10.0)
100 to 200: Intervention: 23 (57.5), Control: 15 (37.5)
200+ : Intervention:10 (25.0), Control: 21 (52.5)
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Patients:
Administrative data study:all diabetic patients > 40 years of age in Ontario; Intervention:
n = 467,713; Control: 466,076
Clinical data study:n of participating patients: Intervention: n = 795; Control: 797 pa-
tients with diabetes aged > 18 years who were seen in the office at least once between
July 2009 and March 2010, and who fulfil the Clinical Practice Guidelines’ definition
of being at ”high risk for CV events“:
Exclusion criteria: Residents of long-term care facilities. Individuals who could not be
assigned to a family practice were excluded
Characteristics of participants:
Administrative data study:
Age, mean (SD): Intervention: 64.3 (12.4); Control: 64.2 (12.4)
Male: Intervention: 246,741 (52.8); Control: 245,204 (52.6)
Diabetes type: no information
Diabetes duration, yrs: < 2 Intervention: 76,547 (16.4), Control: 77,011 (16.5)
yrs 2 to < 5: Intervention:112,509 (24.1), Control: 112,543 (24.1)
yrs 5 to < 10: Intervention: 127,375 (27.2), Control: 126,831 (27.2)
yrs 10+: Intervention: 151,282 (37.3), Control: 149,691 (32.1)
Previous cardiovascular disease: Intervention: 30,108 (6.4), Control: 29,801 (6.4)
Hypertension; Intervention:318,015 (68.0), Control: 317,941 (68.2)
Clinical data study:
Age, mean (SD), y Intervention:65.9 (10.3), Control: 65.5 (10.6)
Male: Intervention: 412 (51.8), Control: 429 (53.8)
Diabetes type: Type 1 14 (1.8) 11 (1.4); Type 2 781 (98.2) 786 (98.6)
Diabetes duration, y: <2 Intervention: 145 (18.2), Control: 120 (15.1)
2-5 Intervention:196 (24.7), Control: 183 (23.0)
5-10 Intervention: 195 (24.5), Control: 214 (26.9)
10+ Intervention: 252 (31.7), Control: 275 (34.5)
Previous cardiovascular disease Intervention: 317 (39.9), Control: 331 (41.5)
Hypertension: Intervention:754 (94.8), Control: 767 (96.2)
Losses to follow-up and withdrawals: No information about the clinical study (none
from the administrative study)
Setting: Family practices
Location (rural/urban):urban and rural Ontario areas
Country: Canada
Interventions Aims: To evaluate the effectiveness of an educational toolkit focusing on cardiovascular
disease screening and risk reduction in people with diabetes
Type of intervention: Passive
Type of guideline tool: printed educational materials (CVD toolkit):The cardiovascular
disease toolkit was a collection of printed educational materials, packaged in a brightly-
coloured box with CDA branding, sent to Canadian family physicians. The contents
included an introductory letter from the Chair of the practice guidelines’ Dissemina-
tion and Implementation Committee; an eight-page summary of selected sections of
the practice guidelines targeted towards family physicians; a four-page synopsis of the
key guideline elements pertaining to cardiovascular disease risk; a small double-sided
laminated card with a simplified algorithm for cardiovascular risk assessment, vascular
protection strategies, and screening for cardiovascular disease; and a pad of tear-off sheets
for patients with a cardiovascular risk self-assessment tool and a list of recommended
35Tools developed and disseminated by guideline producers to promote the uptake of their guidelines (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Shah 2014 (Continued)
risk reduction strategies
Guideline developers: Canadian Diabetes Association (CDA)
Delivery: By mail
Timing: Delivered simultaneously with the updated guideline
Duration of intervention: One-off
Control: Control providers received the Canadian Diabetes Association newsletter,
which included the revised GL
Follow-up time: 10 months
Outcomes Main outcomes:
• Death or non-fatal MI (administrative data study)
• Prescription for statin (clinical data study)
Other (secondary) outcomes:
• Clinical events (admin study): all-cause death, MI, MI or unstable angina, stroke,
stroke or TIA, and other composite outcomes
• CAD assessment (admin study): electrocardiogram, cardiac stress test and nuclear
imaging, coronary angiography, coronary revascularisation processes, cardiology or
internal medicine visits
• Medication initiation (admin study): ACEI/ARB, statin, glucose-lowering drug,
insulin, and nitrate
• Proportion of patients prescribed an angiotensin converting enzyme inhibitor or
angiotensin blocker (clinical study)
• Various intermediate measures (e.g. HbA1c, BP etc) (clinical study)
• Clinical inertia.(clinical study)
Notes Ethical approval and informed consent obtained (yes/no): The study was approved
by the Research Ethics Board of Sunnybrook Health Sciences Centre, Toronto, Ontario
Conflict of interest: BRS was a member of the Guideline Dissemination and Imple-
mentation Committee and the National Research Council of the Canadian Diabetes
Association (CDA) at the time of the study. OB was a member of the Executive of the
Clinical and Scientific Section and the Guideline Dissemination and Implementation
Committee of the CDA at the time of the study. CHYY is currently Chair of the Guide-
line Dissemination and Implementation Committee of the CDA. MMM has served as
an Advisory Board member for the following pharmaceutical companies: Astra Zeneca,
Bristol-Myers Squibb, Eli Lilly and Company, Glaxo Smith Kline, Hoffman La Roche,
Novartis, Novo Nordisk, and Pfizer. JAP has served as both a guest academic editor and
a reviewer for PLOS Medicine
Funding: The study was funded by an operating grant from the Canadian Institutes for
Health Research (CIHR) and the Heart and Stroke Foundation of Canada. BRS receives
salary support from the CIHR, and previously received support from the Canadian
Diabetes Association. The Institute for Clinical Evaluative Sciences (ICES) is a non-
profit research institute funded by the Ontario Ministry of Health and Long-Term Care
(MOHLTC)
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk “..family practices in the province of On-
tario were allocated 1:1 into the interven-
tion or control group using random num-
ber sequences generated by SAS version 9.
3 (SAS Institute Inc.), stratified by the 14
health regions into which responsibility for
health care delivery in Ontario is divided.
We randomly selected practices from each
of the intervention and control arms, and
randomly selected one physician from each
practice. Each selected physician was con-
tacted, and if willing to participate in the
study,we randomly selected 20 diabetic pa-
tients who had visited the physician dur-
ing the study period, and who fulfilled the
CDA’s definition of being at “high risk for
cardiovascular eventsPatients were selected
using randomnumber sequences generated
by SAS version 9.3 (SAS Institute). Their
charts were reviewed by a trained and expe-
rienced registered nurse, blinded to treat-
ment allocation, who abstracted relevant
data into a computerized data collection
template”
Allocation concealment (selection bias) Low risk See above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk In the clinical study the family physicians
were aware they were part of an interven-
tion trial, but data were retrospectively re-
trieved
Blinding of participants and personnel
(non-objective outcomes)
Low risk Patients did not know they were part of a
trial, and datawere retrospectively retrieved
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Objective outcomes and data (prescription
of statins) retrieved from patient records
Baseline characteristics similar High risk Patient characteristics were similar in the
clinical study. However, there were impor-
tant differences in the type of practices be-
tween groups: more then double the pro-
portion of clinics with 200+ diabetes pa-
tients, and greater proportion of solo prac-
tices in the control group, compared to the
intervention group
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Baseline outcome measures similar Low risk No baseline measure of outcomes in the
clinical data study, but baseline levels of
statins prescribed reported in the admin
study
Incomplete outcome data (attrition bias)
All outcomes
Low risk The clinical study data were collected from
patient records
Selective reporting (reporting bias) Unclear risk Some of the outcomes listed in the trial pro-
tocol (i.e. BMI and waist circumference)
were not reported in the paper
Other bias Unclear risk Endocrinologist in Ontario also received
the intervention tool, but were not part of
the study. However, 18% of the diabetes
patients in Ontario were treated by both
GPs and endocrinologists, which may have
biased the results
ACEI/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker
BMI: body mass index
BP: blood pressure
CCECQA: Committee for Co-ordinating Clinical Evaluation and Quality in Aquitaine
C-RCT: cluster-randomised controlled trial
HbA1c: glycosylated haemoglobin
ICC: intraclass correlation coefficient
MI: myocardial infarction
PORT: Pneumonia Patient Outcomes Research Team
SD: standard deviation
TIA: transient ischaemic attack
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Allegranzi 2013 Evaluation of WHO hand-hygiene guideline kit. Ineligible study design
Baker 2001 The guideline implementation tools were not developed by existing guideline producers
Bosch 2014 Protocol of a cluster-RCT. Control will not receive guideline only
Chan 2013 One of the authors (not an existing guideline developing body) developed both the guideline and the tool.
Comparison was not guideline only
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De Beurs 2015 Eligible intervention and study design, but ineligible outcomes
Eccles 2002 C-RCT: Tools not developed by existing guideline developers
Eccles 2007 C-RCT.Tools not developed by existing guideline developers
Flottorp 2002 Tools not developed by existing guideline developers
Fretheim 2006 Tools not developed by existing guideline developers
Overbeek 2010 Tool not developed by existing guideline developers
Robling 2002 The tool was not developed by existing guideline producers
Rood 2005 Tools not developed by existing guidelines developers
Rycroft-Malone 2012 Tools not developed, but supported by, the guideline developers (RCN/RCA)
Witt 2004 Tool not developed by existing guideline developers
Characteristics of studies awaiting assessment [ordered by study ID]
Maximov 2012
Methods Study design: C-RCT
Participants Healthcare providers: 16 general practitioners/clusters who completed the trial (10 from the intervention group, 6
from the usual-care group)
Patients: 92 patients with knee and hip osteoarthritis (63 in the intervention group, 29 in the usual-care group)
Interventions 1-day didactic educational meeting, provision of the printed guideline and patient brochures
Outcomes Patient’s outcomes investigated: WOMAC pain and stiffness scores, body mass index and self-reported treatment
received (oral NSAID, physical exercise, alternative treatment) at 6 and 12 months after the intervention
Notes Conference abstract only
Van Driel 2007
Methods Study design: C-RCT
Participants Healthcare providers: general practitioners in Flanders, Belgium
Interventions Quality circles: self-ledmeetings using material introduced to the group moderator by a member of the research team
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Outcomes Adherence to guidelines
Notes
Characteristics of ongoing studies [ordered by study ID]
Salbach 2014
Trial name or title
Methods C-RCT
Participants Healthcare providers: 20 rehabilitation hospitals/inpatient stroke rehabilitation teams
Patients: people suffering from stroke
Interventions Multicomponent intervention: 2 clinician facilitators per hospital attended a 2-day workshop to receive train-
ing to apply a treatment guideline (18 recommendations) and identify barriers and strategies for implemen-
tation. They also received copies of the treatment recommendations, treatment protocols, presentation slides,
pocket cards, and protected time weekly to facilitate implementation over a 10-week period
Control condition: Copies of the treatment recommendations (the guideline), a video, and a handbook on
using outcome measures
Outcomes Rate of implementation of guideline recommendations
Starting date
Contact information
Notes Conference abstract only.
Te Boveldt 2011
Trial name or title
Methods Study design: C-RCT
Participants Healthcare providers: 6 oncology outpatient clinics of hospitals in the South-eastern region of theNetherlands,
with 3 hospitals in the intervention and 3 in the control condition
Interventions A Short Message Service with Interactive Voice Response (SVSIVR) will be used with the aim to improve
pain reporting, pain measurement and adequate pain therapy for people with cancer. The intervention also
includes training of professionals (medical oncologists, nurses, and general practitioners)
Outcomes Pain reporting, pain measurement, adequate pain therapy and pain intensity
Starting date
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Contact information E-mail: n.teboveldt@anes.umcn.nl
Adress: Department Anesthesiology, Pain and Palliative Medicine, Radboud University Nijmegen Medical
Centre (RUNMC), Nijmegen, 6500 HB, The Netherlands
Notes Protocol only
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
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1Khunti 1998. Development of evidence-based review criteria for the management of patients with depression in general practice. No
published version of the guideline found.
2Bekkering 2003. Dutch physiotherapy guidelines for low back pain.
3Saillour Glénisson 2001. Guidelines for thyroid function tests in adults.
4Shah 2014. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee: Canadian Diabetes Association 2008
clinical practice guidelines for the prevention and management of diabetes in Canada.
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Table 2. Guideline tool development and delivery
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Table 2. Guideline tool development and delivery (Continued)













cian visits to mon-
itor blood pressure.





of a 3-year-old prac-
tice guideline on
anti-anginal therapy











1Bero 1998 Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the imple-
mentation of research findings.
2Davis 1995 Changing physician performance. A systematic review of the effect of continuing medical education strategies.
3Wensing 1998 Implementing guidelines and innovations in general practice: which interventions are effective?
4Grimshaw 1995 Developing and implementing clinical practice guidelines.
5 Davis 1997. Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence
in the adoption of clinical practice guidelines.
6Murrey 1992 Implementing clinical guidelines: a quality management approach to reminder systems.
7Grimshaw 1993. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations.
8Weingarten 2000. Translating practice guidelines into patient care: guidelines at the bedside.
9Grimshaw 2006. Towards evidence-based quality improvement: evidence (and its limitation) of the effectiveness of guideline dissem-
ination and implementation strategies 1966-1998.
10Giguère 2012. Printed educational materials: effects on professional practice and healthcare outcomes.
11Bebb 2007. A cluster randomised controlled trial of the effect of a treatment algorithm for hypertension in patients with type 2
diabetes.
12 Beaulieu 2004. Drug treatment of stable angina pectoris and mass dissemination of therapeutic guidelines: a randomized controlled
trial.
13Not applicable
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Table 3. Intervention components














Bekkering 2005 The content of
the strategy was
determined







ment of the clin-
ical guidelines
- 2 interactive train-
ing sessions, each
lasting 2½ hours,












Daucourt 2003 - - - Pocket memoran-
dum card.
- Test request form.









Shah 2014 - - - - - Printed educa-
tional materials
Table 4. Results: Other outcomes











Bekkering 2005 - Quality of Life









47Tools developed and disseminated by guideline producers to promote the uptake of their guidelines (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.















Note: results for 26




The costs (Euro) of re-
leasing a new guide-




















tion:45 ± 7, n = 181;
Control: 45 ± 7, n =
223; P = 0.71
SF-12 mental health
composite score: In-
tervention: 45 ± 6;
Control: 45 ± 7, P =
0.71
Patient satisfaction




vention: 12 (5.3), n
= 228; Control: 11
(4.0), n = 273, P = 0.
67
Be-
lieved length of stay








09 (0.83 to 1.43), P
= 0.55
Workers: 0.85 (0.54








vention: 22 (8), n =
283; Control: 29 (9)




tion: 15 (5); Con-
trol: 23 (7), P = 0.44
Length of index hos-
pital (days) stay, me-
dian (IQR): Inter-
vention: 5.0 (3.0 to
7.0);Control: 5.0 (3.
0 to 8.0); Hazard ra-
tio (95% CI): 1.16











3.0 (2.0 to 5.0),n =
283; Control: 4.0 (2.
6 to 6.0), n = 325;
Hazard ratio (95%
CI): 1.23 (1.00 to 1.
52), P = 0.06
-
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Table 4. Results: Other outcomes (Continued)
Shah 2014 Clinical data study:
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8%, OR 0.85 (0.63
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725 (90.1%); OR 0.
73, 95% CI 0.42 to


















OR, range: from 0.
96 to 1.00, P values
from 0.02 to 0.83
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Table 4. Results: Other outcomes (Continued)
11.8%; Control: 13.
0%, OR 0.98 (0.48
to 1.98), P = 0.95
When blood pres-
sure > 140/90: Inter-
vention: 5.6%; Con-
trol: 7.2%, OR 0.67
(0.25 to 1.82), P = 0.
43
When LDL choles-
terol > 3.0 mmol/
L: Intervention: 43.
5%; Control: 45.
2%, OR 0.94 (0.53
to 1.67), P = 0.83
Administrative












stroke or TIA, and
combined out-
comes): OR: from 0.
98 to 1.04, P values
from 0.21 to 0.96
1EQ-5D: a standardised instrument for use as a measure of health outcome.The EQ-5D has five dimensions: mobility, self-care, usual
activity,pain/discomfort and anxiety/depression. Each dimension has three levels, no problems, some problems and serious problems.
Hence, EQ-5D has 243 possible health states. Utility values of the general public for these health states as measured with the time
tradeoff technique on a random sample of the adult population of the United Kingdom, the MVH-A1 tariff, were applied in this
study. The scores range from −0.594 (worst situation) to 1.0 (perfect health).
2The direct costs consisted of costs of the dissemination of the guideline and the costs of the healthcare utilisation of the patients. Prices
for the year 2002.
3SF-12 health scores were assessed in all patients able to provide reliable self-report data during the 30-day interview, excluding 6
intervention-arm and 6 control-arm patients with missing data.
4Patient satisfaction with care was assessed for all patients with a 30-day interview that was not completed by a paid caregiver, excluding
four intervention-arm and two control-arm patients with missing data. An additional two patients in the intervention arm and six
patients in the control arm were hospitalised for the full 30 days and were not asked about length of hospital stay. SF-12, 12-Item Short
Form was used.
5Return to usual activities among non-workers was assessed for 183 intervention arm and 219 control arm patients not employed
at baseline who completed a 30-day interview. Return to usual activities among workers was assessed in 59 intervention-arm and
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59 control-arm patients employed at baseline. Return to work was assessed among 54 intervention-arm and 53 control-arm patients
employed at baseline.
6Mortality, medical complications, and return to work and usual activities were adjusted for pneumonia severity risk class.
7Rehospitalisation within 30 days of the index admission was assessed for all patients who were discharged alive from either the index
hospitalisation or another acute-care facility (if transferred to an acute-care facility from the index hospitalisation).
8Fluid fasting times assessed by local investigator asking the patient about the fasting time, and checking this information against
medical notes.
9Cost for designing, editing, reproducing, and posting need when applied to 170 acute trusts.
10Cost of providing 170 acute trusts with implementation support through a web-based resource championed through opinion
leadership. This includes development costs for the tool (which for this project were in-house costs, in other cases external agencies may
have to be used which are likely to be three times higher), publicity materials, training materials and opinion leader time and activity.
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tices (8797 patients)
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A P P E N D I C E S
Appendix 1. Medline search strategies
MEDLINE (OvidSP) (1946 to present, In process) - February 2016
# Searches
1 (“United States Agency for Healthcare Research and Quality”/ or Health Maintenance Organization/) and practice guidelines
as topic/
2 (“United StatesAgency forHealthcareResearch andQuality”/ orHealthMaintenanceOrganization/) andGuidelineAdherence/
3 (health maintenance organi?ation* or hmo? or Aetna or Blue Cross Blue Shield Association or CIGNA or Kaiser Permanente
or Humana or Health Net or UnitedHealth Group or Wellpoint or AHCPR).ti,in. and (guideline* or guidance or standard*1
or pathway*1 or protocol*1).ti
4 1 or 2 or 3
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(Continued)
5 “comment on”.cm. or systematic review.ti. or literature review.ti. or editorial.pt. or meta-analysis.pt. or news.pt. or review.pt
6 4 not 5
7 exp animals/ not humans/
8 6 not 7
9 limit 8 to yr=“1998 -Current”
10 *Guideline Adherence/
11 (guideline* and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
12 (guidance and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
13 (standard? and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
14 (pathway? and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
15 (protocol? and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
16 10 or 11 or 12 or 13 or 14 or 15
17 (national adj3 (guideline*1 or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
18 (regional adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
19 (society adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
20 (association adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
21 (academy adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
22 (board adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
23 (institute? adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
24 (ministry adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
25 (department? adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
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(Continued)
26 ((health maintenance organi?ation* or hmo? or Aetna or Blue Cross Blue Shield Association or CIGNA or Kaiser Permanente
or Humana or Health Net or UnitedHealth Group or Wellpoint) and (guideline* or guidance or standard*1 or pathway*1 or
protocol*1)).ti,ab
27 exp Managed Care Programs/ and (guideline* or guidance or standard*1 or pathway*1 or protocol*1).ti,ab,hw
28 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
29 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere* or non-
concord* or nonconcord* or non-complian* or noncomplian*).ti,ab,hw
30 28 and 29
31 practice guidelines as topic/
32 (practice adj3 (guideline*1 or guidance or standard*1 or pathway*1)).ti,ab
33 (clinical adj3 (guideline*1 or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
34 31 or 32 or 33
35 Guideline Adherence/
36 Health Plan Implementation/
37 (guideline* adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
38 (guidance adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
39 (standard? adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
40 (pathway? adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
41 (protocol? adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
42 35 or 36 or 37 or 38 or 39 or 40 or 41
43 34 and 42
44 16 or 30 or 43
45 “comment on”.cm. or systematic review.ti. or literature review.ti. or editorial.pt. or meta-analysis.pt. or news.pt. or review.pt
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(Continued)
46 44 not 45
47 exp animals/ not humans/
48 46 not 47
49 randomized controlled trial.mp. or controlled clinical trial.pt. or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or
randomly.ab. or trial.ti
50 48 and 49





56 (intervention* adj6 (clinician* or collaborat* or community or complex or DESIGN* or doctor* or educational or family
doctor* or family physician* or family practitioner* or financial or GP or general practice* or hospital* or impact* or improv*
or individuali?e* or individuali?ing or interdisciplin* or multicomponent or multi-component or multidisciplin* or multi-
disciplin* or multifacet* or multi-facet* or multimodal* or multi-modal* or personali?e* or personali?ing or pharmacies or
pharmacist* or pharmacy or physician* or practitioner* or prescrib* or prescription* or primary care or professional* or provider*
or regulatory or regulatory or tailor* or target* or team* or usual care)).ab
57 (collaborativ* or collaboration* or tailored or personali?ed).ti,ab
58 (exp hospitals/ or exp Hospitalization/ or exp Patients/ or exp Nurses/ or exp Nursing/) and (study.ti. or evaluation studies as
topic/)
59 demonstration project*.ti,ab.
60 (pre-post or “pre test*” or pretest* or posttest* or “post test*” or (pre adj5 post)).ti,ab
61 (pre-workshop or post-workshop or (before adj3 workshop) or (after adj3 workshop)).ti,ab
62 ((study adj3 aim?) or “our study”).ab.
63 (before adj10 (after or during)).ti,ab.
64 (“quasi-experiment*” or quasiexperiment* or “quasi random*” or quasirandom* or “quasi control*” or quasicontrol* or ((quasi*
or experimental) adj3 (method* or study or trial or design*))).ti,ab,hw
65 (“time series” adj2 interrupt*).ti,ab,hw.
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(Continued)
66 (time points adj3 (over or multiple or three or four or five or six or seven or eight or nine or ten or eleven or twelve or month*





71 (multicentre or multicenter or multi-centre or multi-center).ti
72 random*.ti,ab. or controlled.ti.
73 (control adj3 (area or cohort? or compar? or condition or group? or intervention? or participant? or study)).ab
74 (cluster* adj3 (random* or trial*)).ti,ab.
75 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or
73 or 74
76 48 and 75
77 limit 76 to yr=“1998 -Current”
78 9 or 51 or 77
79 (2013* or 2014* or 2015*).ed,dp,yr.
80 9 and 79
81 51 and 79
82 77 and 79
Appendix 2. Embase search strategy
1 (Health Maintenance Organization/ or managed care organization/ or preferred provider organization/ or pharmacy benefit
manager/) and practice guideline/
2 (Health Maintenance Organization/ or managed care organization/ or preferred provider organization/ or pharmacy benefit
manager/) and (guideline*1 or guidance or standard*1 or pathway*1 or protocol*1).ti
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(Continued)
3 (health maintenance organi?ation* or hmo? or Aetna or Blue Cross Blue Shield Association or CIGNA or Kaiser Permanente
or Humana or Health Net or UnitedHealth Group or Wellpoint or AHCPR).ti,in. and (guideline* or guidance or standard*1
or pathway*1 or protocol*1).ti
4 1 or 2 or 3
5 review.ti.
6 (animal$ not human$).sh,hw. or (rat or rats or cow or cows or chicken? or horse or horses or mice or mouse or bovine or animal?
).ti
7 5 or 6
8 4 not 7
9 limit 8 to yr=“1998 -Current”
10 (guideline* and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
11 (guidance and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
12 (standard? and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
13 (pathway? and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
14 (protocol? and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
15 10 or 11 or 12 or 13 or 14
16 (national adj3 (guideline*1 or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
17 (regional adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
18 (society adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
19 (association adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
20 (academy adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
21 (board adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
22 (institute? adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
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(Continued)
23 (ministry adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
24 (department? adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
25 ((health maintenance organi?ation* or hmo? or Aetna or Blue Cross Blue Shield Association or CIGNA or Kaiser Permanente
or Humana or Health Net or UnitedHealth Group or Wellpoint) and (guideline* or guidance or standard*1 or pathway*1 or
protocol*1)).ti,ab
26 exp managed care/ and (guideline* or guidance or standard*1 or pathway*1 or protocol*1).ti,ab,hw
27 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
28 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere* or non-
concord* or nonconcord* or non-complian* or noncomplian*).ti,ab,hw
29 27 and 28
30 *practice guideline/
31 (practice adj3 (guideline*1 or guidance or standard*1 or pathway*1)).ti,ab
32 (clinical adj3 (guideline*1 or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
33 30 or 31 or 32
34 (guideline* adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
35 (guidance adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
36 (standard? adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
37 (pathway? adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
38 (protocol? adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
39 34 or 35 or 36 or 37 or 38
40 33 and 39
41 15 or 29 or 40
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(Continued)
42 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind$) or (singl$ adj blind$) or
assign$ or allocat$ or volunteer$).ti,ab. or crossover-procedure/ or double-blind procedure/ or randomized controlled trial/ or
single-blind procedure/
43 41 and 42
44 review.ti.
45 (animal$ not human$).sh,hw. or (rat or rats or cow or cows or chicken? or horse or horses or mice or mouse or bovine or animal?
).ti
46 44 or 45
47 43 not 46
48 limit 47 to yr=“1998 -Current”
49 intervention?.ti. or (intervention? adj6 (clinician? or collaborat$ or community or complex or DESIGN$ or doctor? or educa-
tional or family doctor? or family physician? or family practitioner? or financial or GP or general practice? or hospital? or impact?
or improv$ or individuali?e? or individuali?ing or interdisciplin$ or multicomponent or multi-component or multidisciplin$ or
multi-disciplin$ or multifacet$ or multi-facet$ or multimodal$ or multi-modal$ or personali?e? or personali?ing or pharmacies
or pharmacist? or pharmacy or physician? or practitioner? or prescrib$ or prescription? or primary care or professional$ or
provider? or regulatory or regulatory or tailor$ or target$ or team$ or usual care)).ab
50 (pre-intervention? or preintervention? or “pre intervention?” or post-intervention? or postintervention? or “post intervention?
”).ti,ab
51 (hospital$ or patient?).hw. and (study or studies or care or health$ or practitioner? or provider? or physician? or nurse? or nursing
or doctor?).ti,hw
52 demonstration project?.ti,ab.
53 (pre-post or “pre test$” or pretest$ or posttest$ or “post test$” or (pre adj5 post)).ti,ab
54 (pre-workshop or post-workshop or (before adj3 workshop) or (after adj3 workshop)).ti,ab
55 trial.ti. or ((study adj3 aim?) or “our study”).ab.
56 (before adj10 (after or during)).ti,ab.
57 (time points adj3 (over or multiple or three or four or five or six or seven or eight or nine or ten or eleven or twelve or month$
or hour? or day? or “more than”)).ab
58 pilot.ti.
59 (multicentre or multicenter or multi-centre or multi-center).ti
60 random$.ti,ab. or controlled.ti.
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(Continued)
61 *experimental design/ or *pilot study/ or quasi experimental study/
62 (“quasi-experiment$” or quasiexperiment$ or “quasi random$” or quasirandom$ or “quasi control$” or quasicontrol$ or (
(quasi$ or experimental) adj3 (method$ or study or trial or design$))).ti,ab
63 (“time series” adj2 interrupt$).ti,ab.
64 or/49-63
65 41 and 64
66 review.ti.
67 (animal$ not human$).sh,hw. or (rat or rats or cow or cows or chicken? or horse or horses or mice or mouse or bovine or animal?
).ti
68 66 or 67
69 65 not 68
70 9 or 48 or 69
71 (2013* or 2014* or 2015*).em,dp,yr.
72 9 and 71
73 48 and 71
74 69 and 71
Appendix 3. Psychinfo search strategy
1 (Health Maintenance Organizations/ or exp Professional organizations/ or Government Agencies/) and Treatment Guidelines/
2 (Health Maintenance Organizations/ or exp Professional organizations/ or Government Agencies/) and (guideline* or guidance
or standard*1 or pathway*1 or protocol*1).ti
3 (health maintenance organi?ation* or hmo? or Aetna or Blue Cross Blue Shield Association or CIGNA or Kaiser Permanente
or Humana or Health Net or UnitedHealth Group or Wellpoint or AHCPR).ti,in. and (guideline* or guidance or standard*1
or pathway*1 or protocol*1).ti
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4 1 or 2 or 3
5 review.ti.
6 (rat or rats or cow or cows or chicken? or horse or horses or mice or mouse or bovine or animal?).ti. or exp animals/ or animal?.
ti,id,hw
7 5 or 6
8 4 not 7
9 limit 8 to yr=“1998 -Current”
10 (guideline* and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
11 (guidance and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
12 (standard? and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
13 (pathway? and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
14 (protocol? and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
15 10 or 11 or 12 or 13 or 14
16 (national adj3 (guideline*1 or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
17 (regional adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
18 (society adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
19 (association adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
20 (academy adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
21 (board adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
22 (institute? adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
23 (ministry adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
24 (department? adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
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25 ((health maintenance organi?ation* or hmo? or Aetna or Blue Cross Blue Shield Association or CIGNA or Kaiser Permanente
or Humana or Health Net or UnitedHealth Group or Wellpoint) and (guideline* or guidance or standard*1 or pathway*1 or
protocol*1)).ti,ab
26 exp Managed Care/ and (guideline* or guidance or standard*1 or pathway*1 or protocol*1).ti,ab,hw
27 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
28 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere* or non-
concord* or nonconcord* or non-complian* or noncomplian*).ti,ab,hw
29 27 and 28
30 Treatment Guidelines/
31 (practice adj3 (guideline*1 or guidance or standard*1 or pathway*1)).ti,ab
32 (clinical adj3 (guideline*1 or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
33 30 or 31 or 32
34 (guideline* adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
35 (guidance adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
36 (standard? adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
37 (pathway? adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
38 (protocol? adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
39 34 or 35 or 36 or 37 or 38
40 33 and 39
41 15 or 29 or 40
42 (random or trial* or controlled stud or placebo* or ((singl* or doubl* or trebl* or tripl*) adj2 (blind* or mask*)) or cross over or
crossover or factorial* or assign* or allocat* or volunteer*).ti,ab,hw,id. or treatment effectiveness evaluation/ or mental health
program evaluation/ or exp experimental design/ or “2000”.md
43 41 and 42
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44 review.ti.
45 (rat or rats or cow or cows or chicken? or horse or horses or mice or mouse or bovine or animal?).ti. or exp animals/ or animal?.
ti,id,hw
46 44 or 45
47 43 not 46
48 limit 47 to yr=“1998 -Current”
49 intervention?.ti. or (intervention? adj6 (clinician? or collaborat$ or community or complex or DESIGN$ or doctor? or educa-
tional or family doctor? or family physician? or family practitioner? or financial or GP or general practice? or hospital? or impact?
or improv$ or individuali?e? or individuali?ing or interdisciplin$ or multicomponent or multi-component or multidisciplin$ or
multi-disciplin$ or multifacet$ or multi-facet$ or multimodal$ or multi-modal$ or personali?e? or personali?ing or pharmacies
or pharmacist? or pharmacy or physician? or practitioner? or prescrib$ or prescription? or primary care or professional$ or
provider? or regulatory or regulatory or tailor$ or target$ or team$ or usual care)).ab
50 (pre-intervention? or preintervention? or “pre intervention?” or post-intervention? or postintervention? or “post intervention?
”).ti,ab
51 (hospital$ or patient?).hw. and (study or studies or care or health$ or practitioner? or provider? or physician? or nurse? or nursing
or doctor?).ti,hw
52 demonstration project?.ti,ab.
53 (pre-post or “pre test$” or pretest$ or posttest$ or “post test$” or (pre adj5 post)).ti,ab
54 (pre-workshop or post-workshop or (before adj3 workshop) or (after adj3 workshop)).ti,ab
55 trial.ti. or ((study adj3 aim?) or “our study”).ab.
56 (before adj10 (after or during)).ti,ab.
57 (“quasi-experiment$” or quasiexperiment$ or “quasi random$” or quasirandom$ or “quasi control$” or quasicontrol$ or (
(quasi$ or experimental) adj3 (method$ or study or trial or design$))).ti,ab,hw
58 (“time series” adj2 interrupt$).ti,ab,hw.
59 (time points adj3 (over or multiple or three or four or five or six or seven or eight or nine or ten or eleven or twelve or month$
or hour? or day? or “more than”)).ab
60 pilot.ti.
61 (multicentre or multicenter or multi-centre or multi-center).ti
62 random$.ti,ab. or controlled.ti.
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63 (control adj3 (area or cohort? or compare? or condition or design or group? or intervention? or participant? or study)).ab. not
(controlled clinical trial or randomized controlled trial).pt
64 experimental design/ or between groups design/ or quantitative methods/ or quasi experimental methods/
65 or/49-64
66 41 and 65
67 review.ti.
68 (rat or rats or cow or cows or chicken? or horse or horses or mice or mouse or bovine or animal?).ti. or exp animals/ or animal?.
ti,id,hw
69 67 or 68
70 66 not 69
71 limit 70 to yr=“1998 -Current”
72 9 or 48 or 71
73 (2013* or 2014* or 2015*).dp,up,yr.
74 9 and 73
75 48 and 73
76 71 and 73
Appendix 4. Cinahl search strategy
1 ( (MH “Health Maintenance Organizations”) OR (MH “Independent Practice Associations”) OR (MH “Preferred Provider
Organizations”) OR (MH “Provider-Sponsored Organizations”) ) AND (MH “Practice Guidelines”)
2 ( (MH “Health Maintenance Organizations”) OR (MH “Independent Practice Associations”) OR (MH “Preferred Provider
Organizations”) OR (MH “Provider-Sponsored Organizations”) ) AND (MH “Guideline Adherence”)
3 ( TI ( (healthmaintenance organi?ation* or hmo? or Aetna or BlueCross Blue Shield Association orCIGNAorKaiser Permanente
or Humana or Health Net or UnitedHealth Group or Wellpoint or AHCPR) ) OR AF ( (health maintenance organi?ation*
or hmo? or Aetna or Blue Cross Blue Shield Association or CIGNA or Kaiser Permanente or Humana or Health Net or
UnitedHealth Group or Wellpoint or AHCPR) ) ) AND TI ( guideline* or guidance or standard or standards or pathway or
pathways or protocol or protocols )
4 1 OR 2 OR 3
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5 TI review
6 (MH “Animals+”) NOT (MH “Human”)
7 TI ( rat or rats or cow or cows or chicken? or horse or horses or mice or mouse or bovine or animal? ) OR MW animal?
8 5 OR 6 OR 7
9 4 NOT 8
10 TI ( (guideline* and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)) ) OR TI ( (guidance and (implement*
or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere* or non-concord* or
nonconcord* or non-complian* or noncomplian*)) ) OR TI ( (standard? and (implement* or uptake* or adopt* or adhere*
or concord* or complian* or comply or non-adhere* or nonadhere* or non-concord* or nonconcord* or non-complian* or
noncomplian*)) ) OR TI ( (pathway? and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply
or non-adhere* or nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)) ) OR TI ( (protocol?
and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere* or non-
concord* or nonconcord* or non-complian* or noncomplian*)) )
11 TI ( (national n3 (guideline*1 or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR
TI ( (regional n3 (guideline* or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR TI
( (society n3 (guideline* or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR TI (
(association n3 (guideline* or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR TI
( (academy n3 (guideline* or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR TI
( (board n3 (guideline* or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR TI (
(institute? n3 (guideline* or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR TI (
(ministry n3 (guideline* or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR TI (
(department? n3 (guideline* or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR TI ( (
(health maintenance organi?ation* or hmo? or Aetna or Blue Cross Blue Shield Association or CIGNA or Kaiser Permanente or
Humana or Health Net or UnitedHealth Group or Wellpoint) and (guideline* or guidance or standard or standards or pathway
or pathways or protocol or protocols)) )
12 AB ( (national n3 (guideline*1 or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR
AB ( (regional n3 (guideline* or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR AB
( (society n3 (guideline* or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR AB (
(association n3 (guideline* or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR AB
( (academy n3 (guideline* or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR AB
( (board n3 (guideline* or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR AB (
(institute? n3 (guideline* or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR AB (
(ministry n3 (guideline* or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR AB (
(department? n3 (guideline* or guidance or standard or standards or pathway or pathways or protocol or protocols)) ) OR AB (
((health maintenance organi?ation* or hmo? or Aetna or Blue Cross Blue Shield Association or CIGNA or Kaiser Permanente or
Humana or Health Net or UnitedHealth Group or Wellpoint) and (guideline* or guidance or standard or standards or pathway
or pathways or protocol or protocols)) )
13 (MH “Managed Care Programs+”) AND TI ( guideline*1 or guidance or standard or standards or pathway or pathways or
protocol or protocols )
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14 (MH “Managed Care Programs+”) AND AB ( guideline*1 or guidance or standard or standards or pathway or pathways or
protocol or protocols )
15 (MH “Managed Care Programs+”) AND MW ( guideline*1 or guidance or standard or standards or pathway or pathways or
protocol or protocols )
16 11 OR 12 OR 13 OR 14 OR 15
17 TI ( implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere* or
non-concord* or nonconcord* or non-complian* or noncomplian* ) OR AB ( implement* or uptake* or adopt* or adhere*
or concord* or complian* or comply or non-adhere* or nonadhere* or non-concord* or nonconcord* or non-complian* or
noncomplian* ) OR MW ( implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere*
or nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian* )
18 16 AND 17
19 (MH “Practice Guidelines”)
20 TI ( (practice n3 (guideline*1 or guidance or standard*1 or pathway*1)) ) OR AB ( (practice n3 (guideline*1 or guidance or
standard*1 or pathway*1)) ) OR TI ( (clinical n3 (guideline*1 or guidance or standard*1 or pathway*1 or protocol*1)) ) OR
AB ( (clinical n3 (guideline*1 or guidance or standard*1 or pathway*1 or protocol*1)) )
21 19 OR 20
22 (MH “Guideline Adherence”)
23 (MH “Program Implementation”) OR (MH “Systems Implementation”)
24 TI ( (guideline* n5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)) ) OR AB ( (guideline* n5 (implement*
or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere* or non-concord* or
nonconcord* or non-complian* or noncomplian*)) )
25 TI ( (guidance n5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)) ) OR AB ( (guidance n5 (implement*
or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere* or non-concord* or
nonconcord* or non-complian* or noncomplian*)) )
26 TI ( (standard? n5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)) ) OR AB ( (standard? n5 (implement*
or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere* or non-concord* or
nonconcord* or non-complian* or noncomplian*)) )
27 TI ( (pathway? n5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)) ) OR AB ( (pathway? n5 (implement*
or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere* or non-concord* or
nonconcord* or non-complian* or noncomplian*)) )
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28 TI ( (protocol? n5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)) ) OR AB ( (protocol? n5 (implement*
or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere* or non-concord* or
nonconcord* or non-complian* or noncomplian*)) )
29 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28
30 21 AND 29
31 10 OR 18 OR 30
32 ( (MH “Clinical Trials”) OR (MH “Double-Blind Studies”) OR (MH “Randomized Controlled Trials”) OR (MH “Single-
Blind Studies”) OR (MH “Triple-Blind Studies”) ) OR ( TI ( (random* or factorial* or crossover* or cross over* or cross-over*
or placebo* or (doubl* n2 blind*) or (singl* n2 blind*) or assign* or allocat* or volunteer*) ) OR AB ( (random* or factorial*
or crossover* or cross over* or cross-over* or placebo* or (doubl* n2 blind*) or (singl* n2 blind*) or assign* or allocat* or
volunteer*) ) )
33 31 AND 32
34 TI review
35 TI ( rat or rats or cow or cows or chicken? or horse or horses or mice or mouse or bovine or animal? ) OR MW animal?
36 (MH “Animals+”) NOT (MH “Human”)
37 34 or 35 or 36
38 33 NOT 37
39 (MH “Quasi-Experimental Studies”)
40 TI ( intervention* ormultiintervention* ormulti-intervention* or postintervention* or post-intervention* or preintervention* or
pre-intervention* ) or AB ( intervention* ormultiintervention* ormulti-intervention* or postintervention* or post-intervention*
or preintervention* or pre-intervention* )
41 TI ( pre-test* or pretest* or posttest* or post-test* ) orAB ( pre-test* or pretest* or posttest* or “post test* )ORTI ( preimplement*”
or pre-implement* ) or AB ( pre-implement* or preimplement* )
42 MH Experimental Studies or Community Trials or Community Trials or Pretest-Posttest Design + or Quasi-Experimental
Studies + Pilot Studies or Policy Studies + Multicenter Studies
43 TI ( (comparative N2 study) or (comparative N2 studies) or evaluation study or evaluation studies ) or AB ( (comparative N2
study) or (comparative N2 studies) or evaluation study or evaluation studies )
44 MH “Multiple Time Series” or MH “Time Series”
45 TI pre w7 post or AB pre w7 post
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46 TI ( ( quasi-experiment* or quasiexperiment* or quasi-random* or quasirandom* or quasi control* or quasicontrol* or quasi*
W3 method* or quasi* W3 study or quasi* W3 studies or quasi* W3 trial or quasi* W3 design* or experimental W3 method*
or experimental W3 study or experimental W3 studies or experimental W3 trial or experimental W3 design* ) ) or AB ( ( quasi-
experiment* or quasiexperiment* or quasi-random* or quasirandom* or quasi control* or quasicontrol* or quasi* W3 method*
or quasi* W3 study or quasi* W3 studies or quasi* W3 trial or quasi* W3 design* or experimental W3 method* or experimental
W3 study or experimental W3 studies or experimental W3 trial or experimental W3 design* ) )
47 TI ( (time point*) or (period* n4 interrupted) or (period* n4multiple) or (period* n4 time) or (period* n4 various) or (period* n4
varying) or (period* n4 week*) or (period* n4 month*) or (period* n4 year*) ) or AB ( (time point*) or (period* n4 interrupted)
or (period* n4 multiple) or (period* n4 time) or (period* n4 various) or (period* n4 varying) or (period* n4 week*) or (period*
n4 month*) or (period* n4 year*) )
48 AB ( before* n10 during or before n10 after ) or AU ( before* n10 during or before n10 after )
49 TI time series or AB time series or AB “before-and-after”
50 (MH “Pilot Studies”)
51 TI pilot
52 TI ( collaborativ* or collaboration* or tailored or personalised or personalized ) or AB ( collaborativ* or collaboration* or tailored
or personalised or personalized )
53 (intervention n6 clinician*) or (intervention n6 community) or (intervention n6 complex) or (intervention n6 design*) or
(intervention n6 doctor*) or (intervention n6 educational) or (intervention n6 family doctor*) or (intervention n6 family
physician*) or (intervention n6 family practitioner*) or (intervention n6 financial) or (intervention n6 GP) or (intervention n6
general practice*) Or (intervention n6 hospital*) or (intervention n6 impact*) Or (intervention n6 improv*) or (intervention n6
individualize*) Or (intervention n6 individualise*) or (intervention n6 individualizing) or (intervention n6 individualising) or
(intervention n6 interdisciplin*) or (intervention n6 multicomponent) or (intervention n6 multi-component) or (intervention
n6 multidisciplin*) or (intervention n6 multi-disciplin*) or (intervention n6 multifacet*) or (intervention n6 multi-facet*) or
(intervention n6 multimodal*) or (intervention n6 multi-modal*) or (intervention n6 personalize*) or(intervention n6 person-
alise*) or (intervention n6 personalizing) or (intervention n6 personalising) or (intervention n6 pharmaci*) or (intervention
n6 pharmacist*) or (intervention n6 pharmacy) or (intervention n6 physician*) or (intervention n6 practitioner*) Or (inter-
vention n6 prescrib*) or (intervention n6 prescription*) or (intervention n6 primary care) or (intervention n6 professional*)
or (intervention* n6 provider*) or (intervention* n6 regulatory) or (intervention n6 regulatory) or (intervention n6 tailor*) or
(intervention n6 target*) or (intervention n6 team*) or (intervention n6 usual care)
54 TI ( demonstration project OR demonstration projects OR preimplement* or pre-implement* or post-implement* or postim-
plement* ) or AB ( demonstration project OR demonstration projects OR preimplement* or pre-implement* or post-imple-
ment* or postimplement* )
55 TI ( pre-workshop or preworkshop or post-workshop or postworkshop or (before n3 workshop) or (after n3 workshop) ) or AB
( pre-workshop or preworkshop or post-workshop or postworkshop or (before n3 workshop) or (after n3 workshop) )
56 TI ( trial or (study n3 aim) or “our study” ) or AB ( (study n3 aim) or “our study” )
57 TI ( multicentre or multicenter or multi-centre or multi-center )
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58 TI ( (control w3 area) or (control w3 cohort*) or (control w3 compar*) or (control w3 condition) or (control w3 group*)
or (control w3 intervention*) or (control w3 participant*) or (control w3 study) ) or AB ( (control w3 area) or (control w3
cohort*) or (control w3 compar*) or (control w3 condition) or (control w3 group*) or (control w3 intervention*) or (control
w3 participant*) or (control w3 study) )
59 TI ( (time points n3 over) or (time points n3 multiple) or (time points n3 three) or (time points n3 four) or (time points n3
five) or (time points n3 six) or (time points n3 seven) or (time points n3 eight) or (time points n3 nine) or (time points n3 ten)
or (time points n3 eleven) or (time points n3 twelve) or (time points n3 month*) or (time points n3 hour*) or (time points n3
day*) or (time points n3 “more than”) ) or AB ( (time points n3 over) or (time points n3 multiple) or (time points n3 three)
or (time points n3 four) or (time points n3 five) or (time points n3 six) or (time points n3 seven) or (time points n3 eight) or
(time points n3 nine) or (time points n3 ten) or (time points n3 eleven) or (time points n3 twelve) or (time points n3 month*)
or (time points n3 hour*) or (time points n3 day*) or (time points n3 “more than”) )
60 39 OR 40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 46 OR 47 OR 48 OR 49 OR 50 OR 51 OR 52 OR 53 OR 54 OR 55
OR 56 OR 57 OR 58 OR 59
61 31 AND 60
62 TI review
63 TI ( rat or rats or cow or cows or chicken? or horse or horses or mice or mouse or bovine or animal? ) OR MW animal?
64 (MH “Animals+”) NOT (MH “Human”)
65 62 OR 63 OR 64
66 61 NOT 65
Appendix 5. Cochrane search strategy
#1 MeSH descriptor: [Health Maintenance Organizations] explode all trees
#2 MeSH descriptor: [United States Agency for Healthcare Research and Quality] explode all trees
#3 #1 or #2
#4 MeSH descriptor: [Practice Guidelines as Topic] explode all trees
#5 MeSH descriptor: [Guideline Adherence] explode all trees
#6 #4 or #5
#7 #3 and #6
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#8 health maintenance organi?ation* or hmo? or Aetna or Blue Cross Blue Shield Association or CIGNA or Kaiser Permanente
or Humana or Health Net or UnitedHealth Group or Wellpoint or AHCPR:ti (Word variations have been searched)
#9 guideline or guidelines or guidance or standard or standards or pathway or pathways or protocol or protocols:ti (Word variations
have been searched)
#10 #8 and #9
#11 #7 or #10
#12 MeSH descriptor: [Guideline Adherence] explode all trees
#13 (guideline* and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)):ti (Word variations have been searched)
#14 (guidance and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)):ti (Word variations have been searched)
#15 (standard* and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)):ti (Word variations have been searched)
#16 (pathway* and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)):ti (Word variations have been searched)
#17 (protocol* and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)):ti (Word variations have been searched)
#18 #12 or #13 or #14 or #15 or #16 or #17
#19 (national near/3 (guideline* or guidance or standard* or pathway* or protocol*)):ti,ab,kw (Word variations have been searched)
#20 (regional near/3 (guideline* or guidance or standard* or pathway* or protocol*)):ti,ab,kw (Word variations have been searched)
#21 (society near/3 (guideline* or guidance or standard* or pathway* or protocol*)):ti,ab,kw (Word variations have been searched)
#22 (association near/3 (guideline* or guidance or standard* or pathway* or protocol*)):ti,ab,kw (Word variations have been
searched)
#23 (academy near/3 (guideline* or guidance or standard* or pathway* or protocol*)):ti,ab,kw (Word variations have been searched)
#24 (board near/3 (guideline* or guidance or standard* or pathway* or protocol*)):ti,ab,kw (Word variations have been searched)
#25 (institute? near/3 (guideline* or guidance or standard* or pathway* or protocol*)):ti,ab,kw (Word variations have been searched)
#26 (ministry near/3 (guideline* or guidance or standard* or pathway* or protocol*))
#27 (department? near/3 (guideline* or guidance or standard* or pathway* or protocol*))
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#28 ((health maintenance organi?ation* or hmo? or Aetna or Blue Cross Blue Shield Association or CIGNA or Kaiser Permanente
or Humana or Health Net or UnitedHealth Group or Wellpoint) and (guideline* or guidance or standard* or pathway* or
protocol*)):ti,ab,kw (Word variations have been searched)
#29 MeSH descriptor: [Managed Care Programs] explode all trees
#30 guideline* or guidance or standard* or pathway* or protocol*:ti,ab,kw (Word variations have been searched)
#31 29 and 30
#32 #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #28 or #31
#33 implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere* or non-
concord* or nonconcord* or non-complian* or noncomplian*:ti,ab,kw (Word variations have been searched)
#34 #32 and #33
#35 MeSH descriptor: [Practice Guidelines as Topic] explode all trees
#36 (practice near/3 (guideline* or guidance or standard* or pathway*)):ti,ab,kw (Word variations have been searched)
#37 (clinical near/3 (guideline* or guidance or standard* or pathway* or protocol*)):ti,ab,kw (Word variations have been searched)
#38 #35 or #36 or #37
#39 MeSH descriptor: [Guideline Adherence] explode all trees
#40 MeSH descriptor: [Health Plan Implementation] explode all trees
#41 (guideline* near/5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)):ti,ab,kw (Word variations have been
searched)
#42 (guidance near/5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)):ti,ab,kw (Word variations have been
searched)
#43 (standard? near/5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)):ti,ab,kw (Word variations have been
searched)
#44 (pathway? near/5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)):ti,ab,kw (Word variations have been
searched)
#45 (protocol? near/5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)):ti,ab,kw (Word variations have been
searched)
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#46 #39 or #40 or #41 or #42 or #43 or #44 or #45
#47 #38 and #46
#48 #11 or #18 or #34 or #47
Appendix 6. Proquest search strategy
Set Search
S9 (S1 OR S2 OR S4 OR S6) AND S5Limits applied
S7 (S1 OR S2 OR S4 OR S6) AND S5
S6 ti(practice guideline* OR clinical guideline* OR practice guidance OR clinical guidance OR practice protocol* OR clinical
protocol* OR practice standard* OR clinical standard* OR practice pathway* OR clinical pathway*) AND ab(implement* OR
uptake* OR adopt* OR adhere* OR concord* OR complian* OR comply OR non-adhere* OR nonadhere* OR non-concord*
OR nonconcord* OR non-complian* OR noncomplian*)
S5 ti(random* OR factorial* OR crossover* OR cross over* OR cross-over* OR placebo* OR blind* OR assign* OR allocat* OR
volunteer*) OR ab(random* OR factorial* OR crossover* OR cross over* OR cross-over* OR placebo* OR blind* OR assign*
OR allocat* OR volunteer*)
S4 ab(((national OR regional OR society OR association OR academy OR board OR institute* OR ministry OR department)
near (guideline* OR guidance OR standard* OR pathway* OR protocol*))) AND ab(implement* OR uptake* OR adopt* OR
adhere* OR concord* OR compliant* OR comply OR non-adhere* OR nonadhere* OR non-concord* OR nonconcord* OR
noncomplian* OR noncomplian*)
S2 ti(health maintenance organi?ation* OR hmo? OR Aetna OR Blue Cross Blue Shield Association OR CIGNA OR Kaiser
Permanente OR Humana OR Health Net OR UnitedHealth Group OR Wellpoint OR AHCPR) AND ti(guideline* OR
guidance OR standard* OR pathway* OR protocol*)
S1 ti(((guideline*or guidance OR standard? OR protocol? OR pathways?) AND (implement* OR uptake* OR adopt* OR adhere*
OR concord* OR complian* OR comply OR non-adhere* OR nonadhere* OR non-concord* OR nonconcord* OR non-
complian* OR noncomplian*)))
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1 TI=((health maintenance organisation* or healthmaintenance organization* or hmo or hmos or Aetna or Blue Cross Blue Shield
Association or CIGNA or Kaiser Permanente or Humana or Health Net or UnitedHealth Group or Wellpoint or AHCPR)
) OR AD=((health maintenance organisation* or health maintenance organization* or hmo or hmos or Aetna or Blue Cross
Blue Shield Association or CIGNA or Kaiser Permanente or Humana or Health Net or UnitedHealth Group or Wellpoint or
AHCPR))
2 TI=(guideline* or guidance or standard* or pathway* or protocol*)
3 2 AND 1
4 TI=review
5 TI=(rat or rats or cow or cows or chicken? or horse or horses or mice or mouse or bovine or animal?)
6 5 OR 4
7 3 NOT 6
8 TI=((guideline* and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)))
9 TI=((guidance and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)))
10 TI=((standard? and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)))
11 TI=((pathway? and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)))
12 TI=((protocol? and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*)))
13 12 OR 11 OR 10 OR 9 OR 8
14 TS=((regional NEAR/3 (guideline* or guidance or standard* or pathway* or protocol*)))
15 TS=((national NEAR/3 (guideline* or guidance or standard* or pathway* or protocol*)))
16 TS=((society NEAR/3 (guideline* or guidance or standard* or pathway* or protocol*)))
17 TS=((association NEAR/3 (guideline* or guidance or standard* or pathway* or protocol*)))
18 TS=((academy NEAR/3 (guideline* or guidance or standard* or pathway* or protocol*)))
19 TS=((board NEAR/3 (guideline* or guidance or standard* or pathway* or protocol*)))
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20 TS=((institute? NEAR/3 (guideline* or guidance or standard* or pathway* or protocol*)))
21 TS=((ministry NEAR/3 (guideline* or guidance or standard* or pathway* or protocol*)))
22 TS=((department? NEAR/3 (guideline* or guidance or standard* or pathway* or protocol*)))
23 TS=((“Managed Care Program*” NEAR/3 (guideline* or guidance or standard* or pathway* or protocol*)))
24 23 OR 22 OR 21 OR 20 OR 19 OR 18 OR 17 OR 16 OR 15 OR 14
25 TS=(implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere* or non-
concord* or nonconcord* or non-complian* or noncomplian*)
26 25 AND 24
27 TS=((practice NEAR/3 (guideline* or guidance or standard* or pathway*))) OR TS=((clinical NEAR/3 (guideline* or guidance
or standard* or pathway* or protocol*)))
28 TS=((guideline* NEAR/5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or
nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*))) OR TS=((guidance NEAR/5 (implement*
or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere* or non-concord* or
nonconcord* or non-complian* or noncomplian*))) OR TS=((standard? NEAR/5 (implement* or uptake* or adopt* or adhere*
or concord* or complian* or comply or non-adhere* or nonadhere* or non-concord* or nonconcord* or non-complian* or
noncomplian*)))ORTS=((pathway?NEAR/5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply
or non-adhere* or nonadhere* or non-concord* or nonconcord* or non-complian* or noncomplian*))) OR TS=((protocol?
NEAR/5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere* or
non-concord* or nonconcord* or non-complian* or noncomplian*)))
29 28 AND 27
30 29 OR 26 OR 13
31 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)
32 31 AND 30
33 32 not 6
34 TI=(intervention*)
35 TS=(((intervention* SAME (clinician* or collaborat* or community or complex or DESIGN* or doctor* or educational or
family doctor* or family physician* or family practitioner* or financial or GP or general practice* or hospital* or impact* or
improv* or individuali*e* or individuali*ing or interdisciplin* or multicomponent or multi-component or multidisciplin* or
multi-disciplin* or multifacet* or multi-facet* or multimodal* or multi-modal* or personali*e* or personali*ing or pharmacies
or pharmacist* or pharmacy or physician* or practitioner* or prescrib* or prescription* or primary care or professional* or
provider* or regulatory or regulatory or tailor* or target* or team* or usual care))))
36 TS=((collaborativ* OR collaboration* OR tailored OR personalised OR personalized))
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37 TS=(((demonstration OR pilot) NEXT project*))
38 TI=(pilot)
39 TS=(((pre-post or “pre test*” or pretest* or posttest* or “post test*” or (pre SAME post))))
40 TS=(((pre-workshop or post-workshop or (before SAME workshop) or (after SAME workshop))))
41 TS=((((study SAME aim*) or “our study”)))
42 TS=(((“quasi-experiment*” or quasiexperiment* or “quasi random*” or quasirandom* or “quasi control*” or quasicontrol* or (
(quasi* or experimental) SAME (method* or study or trial or design*)))))
43 TS=(((“time series” SAME interrupt*)))
44 TS=(((time points SAME (over or multiple or three or four or five or six or seven or eight or nine or ten or eleven or twelve or
month* or hour* or day* or “more than”))))
45 TS=((multicentre or multicenter or multi-centre or multi-center))
46 TS=(((control SAME (area or cohort* or compar* or condition or group* or intervention* or participant* or study))))
47 46 OR 45 OR 44 OR 43 OR 42 OR 41 OR 40 OR 39 OR 38 OR 37 OR 36 OR 35 OR 34
48 30 AND 47




Appendix 8. HMIC search strategy
1 (health maintenance organi?ation* or hmo? or Aetna or Blue Cross Blue Shield Association or CIGNA or Kaiser Permanente
or Humana or Health Net or UnitedHealth Group or Wellpoint or AHCPR).ti,ab. and (guideline* or guidance or standard*1
or pathway*1 or protocol*1).ti
2 (guideline* and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
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3 (guidance and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
4 (standard? and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
5 (pathway? and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
6 (protocol? and (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti
7 1 or 2 or 3 or 4 or 5 or 6
8 (national adj3 (guideline*1 or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
9 (regional adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
10 (society adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
11 (association adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
12 (academy adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
13 (board adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
14 (institute? adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
15 (ministry adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
16 (department? adj3 (guideline* or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
17 ((health maintenance organi?ation* or hmo? or Aetna or Blue Cross Blue Shield Association or CIGNA or Kaiser Permanente
or Humana or Health Net or UnitedHealth Group or Wellpoint) and (guideline* or guidance or standard*1 or pathway*1 or
protocol*1)).ti,ab
18 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere* or non-
concord* or nonconcord* or non-complian* or noncomplian*).ti,ab,hw
20 18 and 19
21 clinical guidelines/
22 (practice adj3 (guideline*1 or guidance or standard*1 or pathway*1)).ti,ab
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23 (clinical adj3 (guideline*1 or guidance or standard*1 or pathway*1 or protocol*1)).ti,ab
24 21 or 22 or 23
25 implementation/
26 (guideline* adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
27 (guidance adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
28 (standard? adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
29 (pathway? adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
30 (protocol? adj5 (implement* or uptake* or adopt* or adhere* or concord* or complian* or comply or non-adhere* or nonadhere*
or non-concord* or nonconcord* or non-complian* or noncomplian*)).ti,ab
31 25 or 26 or 27 or 28 or 29 or 30
32 24 and 31
33 7 or 20 or 32
34 review.ti.
35 33 not 34
36 limit 35 to yr=“1998 -Current”
37 limit 35 to yr=“2013 -Current”
Appendix 9. Trial registers
Trial registers:
Clinicaltrials.gov
(guideline OR guidelines) AND (implementOR implementation
OR adopt OR adoption OR uptake)
Intervention
77Tools developed and disseminated by guideline producers to promote the uptake of their guidelines (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
(guideline OR guidelines) AND (concord OR concordance OR
comply OR compliance OR adherence)
Intervention
(guideline OR guidelines) AND (implementOR implementation
OR adopt OR adoption OR uptake)
Title
(guideline OR guidelines) AND (concord OR concordance OR






Guideline OR guide;ines Intervention




Appendix 10. Grey literature
• Open Grey (http://www.opengrey.eu/)
• Grey Literature Report (New York Academy of Medicine) (http://greylit.org/)
• Joanna Briggs Institute (http://www.joannabriggs.edu.au/Search.aspx)
• Guideline International Network (GIN) (http://www.g-i-n.net/)
• Agency for Healthcare Research and Quality (AHRQ) Guideline Clearing House (http://www.guideline.gov/) and AHRQ (
www.ahrq.gov/)
• NHS Evidence, who accredit CPG producers within and outside the UK and have access to specialist collections of CPGs (
http://www.evidence.nhs.uk/)
• Scottish Intercollegiate Guideline Network (SIGN) (http://www.sign.ac.uk/)
• Organisations that summarise CPGs (e.g. Map of Medicine (http://www.mapofmedicine.com/), Egton Medical Information
Systems Ltd. (EMIS) (http://www.emis-online.com/)
• eGuidelines for primary care (http://www.eguidelines.co.uk/new˙guidelines.php) (eGuidelines)
• National Institute for Health and Clinical Excellence (NICE) (www.nice.org.uk/); NICE Medicine and Prescribing centre
(MPC) (http://www.nice.org.uk/mpc/index.jsp) (previously the The National Prescribing Centre)
• CMA Infobase (http://www.cma.ca/index.php/ci˙id/54316/la˙id/1.htm)
• SAGE - standards and guideline evidence (http://www.partnershipagainstcancer.ca/2009/02/06/sage-standards-and-guidelines-
evidence/)
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Appendix 11. Websites searched
Website name/organisation URL Date Search terms
OpenGrey www.opengrey.eu/ discipline:(06*) AND guideline* AND imple-
ment*
New York Academy of
Medicine: Grey Literature Re-
port
www.greylit.org/
GIRAnet - Guideline imple-













22/06/2015 Search 2: implement*
















www.ahrq.gov/index.html 22/06/2015 (guideline OR guidelines) AND (implement OR
implementing OR implementation)
Joanna Briggs Institute www.joannabriggs.org 23/06/2015 implement*








Guidelines in practice www.guidelinesinpractice.co.
uk
23/06/2015
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American Academy of Neurol-
ogy
(guideline OR guidelines)
AND (implement OR imple-
menting OR implementation)
site: www.aan.com/
American Association of Neu-
rological Surgeons
(guideline OR guidelines)
AND (implement OR imple-
menting OR implementation)
site: www.aans.org/
American College of Chest
Physicians
(guideline OR guidelines)
AND (implement OR imple-
menting OR implementation)
site: www.chestnet.org/
American College of Obstetri-
cians and Gynecologists
(guideline OR guidelines)
AND (implement OR imple-
menting OR implementation)
site: www.acog.org/
American College of Radiology (guide-




American Society for Gastroin-
testinal Endoscopy
(guideline OR guidelines)




tion Education and Research,
Inc.
(guideline OR guidelines)
AND (implement OR imple-
menting OR implementation)
site: www.auanet.org/
British Committee for Stan-
dards in Haematology
(guide-
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Cancer Care Ontario (guideline OR guidelines)








Centers for Disease Control
and Prevention
(guideline OR guidelines)







OR implementing OR imple-
mentation) site: www.cincin-
natichildrens.org
Congress of Neurological Sur-
geons
(guide-




European Academy of Neurol-
ogy
(guide-




European Association of Urol-
ogy
(guide-




Hartford Institute for Geriatric
Nursing
(guideline OR guidelines)
AND (implement OR imple-
menting OR implementation)
site: www.hartfordign.org/
Institute for Clinical Systems
Improvement
(guide-
line OR guidelines) AND (im-
plementOR implementingOR
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AND (implement OR imple-
menting OR implementation)
site: www.ncgc.ac.uk/
New York State Department of
Health
(guideline OR guidelines)
AND (implement OR imple-
menting OR implementation)
site: www.health.ny.gov/
OntarioMinistry of Health and
Long-Term Care
(guideline OR guidelines)






AND (implement OR imple-
menting OR implementation)
site: www.cancercare.on.ca
Royal College of Nursing (guide-




Royal College of Obstetricians
and Gynaecologists
(guideline OR guidelines)
AND (implement OR imple-
menting OR implementation)
site: www.rcog.org.uk/
Society of Obstetricians and
Gynaecologists of Canada
(guide-
line OR guidelines) AND (im-
plementOR implementingOR
implementation) site: sogc.org/
U.S. Preventive Services Task
Force
(guideline OR guidelines)
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University of Michigan Health
System
(guideline OR guidelines)
AND (implement OR imple-
menting OR implementation)
site: www.uofmhealth.org/
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S O U R C E S O F S U P P O R T
Internal sources
• Nuffield Department of Population Health, University of Oxford., UK.
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External sources
• NIHR Cochrane EPOC programme grant, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Two new review authors (AH and LG), who were not involved at the protocol stage, are included in the review team.
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